rearrangement	amino_acid	frame_type	rearrangement_type	templates	reads	frequency	productive_frequency	cdr3_length	v_family	v_gene	v_allele	d_family	d_gene	d_allele	j_family	j_gene	j_allele	v_deletions	d5_deletions	d3_deletions	j_deletions	n2_insertions	n1_insertions	v_index	n1_index	n2_index	d_index	j_index	v_family_ties	v_gene_ties	v_allele_ties	d_family_ties	d_gene_ties	d_allele_ties	j_family_ties	j_gene_ties	j_allele_ties	sequence_tags	v_shm_count	v_shm_indexes	antibody	bio_identity	v_resolved	d_resolved	j_resolved	sample_name	species	locus	product_subtype	kit_pool	sku	test_name	sample_catalog_tags	sample_rich_tags	sample_rich_tags_json	kit_control	total_templates	productive_templates	outofframe_templates	stop_templates	dj_templates	total_rearrangements	productive_rearrangements	outofframe_rearrangements	stop_rearrangements	dj_rearrangements	total_reads	total_productive_reads	total_outofframe_reads	total_stop_reads	total_dj_reads	productive_clonality	productive_entropy	sample_clonality	sample_entropy	sample_amount_ng	sample_cells_mass_estimate	fraction_productive_of_cells_mass_estimate	sample_cells	fraction_productive_of_cells	max_productive_frequency	max_frequency	counting_method	primer_set	sequence_result_status	release_date	upload_date	sample_tags	fraction_productive	order_name	kit_id	total_t_cells	total_templates_agg
TGGGGGACTCAGCTTTGTATTTCTGTGCCAGCAGCGCCCAAGAGAGGTTTGAAGCTTTCTTTGGACAA	CASSAQERFEAFF	In	VDJ	1	70	0.009592983417842949	0.012832263978001834	39	TCRBV09	TCRBV09-01		TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-01	01	3	11	1	7	7	2	23	36	47	43	49			01,02										Vb 1	CASSAQERFEAFF+TCRBV09-01+TCRBJ01-01	TCRBV09-01	TCRBD02-01*02	TCRBJ01-01*01	5660A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment				161	120	39	1	0	128	98	29	1	0	7297	5455	1791	51	0	0.0534780733	6.26096773	0.0522329435	6.63436937				479	0.25057435	0.0612282306	0.0457722358	v2	Human-TCRB-PD2x	Published	08/10/2016 11:24:40	07/05/2016 03:54:28	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment,os censored status (0 = alive, 1=dead):os censored status (0 = alive, 1=dead) 1,overall survival (days):overall survival (days) 1526,pfs censored status (0 = pf, 1=progressed):pfs censored status (0 = pf, 1=progressed) 1,progression free survival (days):progression free survival (days) 428,treatment:nact,type of chemo:carbo/taxol	0.745341594591487	MSKCC- Snyder- P01-01		120.0	
TGGGGGACTCAGCTTTGTATTTCTGTACCAGCAGCGTAGAGGGGGGCCGCTCCTACGAGCAGTACTTCGGGCCG	CTSSVEGGRSYEQYF	In	VDJ	1	27	0.0037001507468822806	0.004949587534372136	45	TCRBV09	TCRBV09-01					TCRBJ02	TCRBJ02-07	01	0	5	1	0	0	4	23	-1	45	39	49			01,02	TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 1	CTSSVEGGRSYEQYF+TCRBV09-01+TCRBJ02-07	TCRBV09-01		TCRBJ02-07*01	5660A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment				161	120	39	1	0	128	98	29	1	0	7297	5455	1791	51	0	0.0534780733	6.26096773	0.0522329435	6.63436937				479	0.25057435	0.0612282306	0.0457722358	v2	Human-TCRB-PD2x	Published	08/10/2016 11:24:40	07/05/2016 03:54:28	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment,os censored status (0 = alive, 1=dead):os censored status (0 = alive, 1=dead) 1,overall survival (days):overall survival (days) 1526,pfs censored status (0 = pf, 1=progressed):pfs censored status (0 = pf, 1=progressed) 1,progression free survival (days):progression free survival (days) 428,treatment:nact,type of chemo:carbo/taxol	0.745341594591487	MSKCC- Snyder- P01-01		120.0	
TCAGGAGACACAGCACGGTATTTCTGTGCCAGCAGCGTAGCGGGGAGCAATCAGCCCCAGCATTTTGGTGAT	CASSVAGSNQPQHF	In	VDJ	1	57	0.007811429354529258	0.010449129239230064	42	TCRBV21	TCRBV21-or09_02	01	TCRBD02	TCRBD02-01	01	TCRBJ01	TCRBJ01-05	01	5	5	3	1	1	0	24	36	-1	37	45														CASSVAGSNQPQHF+TCRBV21-or09_02+TCRBJ01-05	TCRBV21-or09_02*01	TCRBD02-01*01	TCRBJ01-05*01	5660A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment				161	120	39	1	0	128	98	29	1	0	7297	5455	1791	51	0	0.0534780733	6.26096773	0.0522329435	6.63436937				479	0.25057435	0.0612282306	0.0457722358	v2	Human-TCRB-PD2x	Published	08/10/2016 11:24:40	07/05/2016 03:54:28	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment,os censored status (0 = alive, 1=dead):os censored status (0 = alive, 1=dead) 1,overall survival (days):overall survival (days) 1526,pfs censored status (0 = pf, 1=progressed):pfs censored status (0 = pf, 1=progressed) 1,progression free survival (days):progression free survival (days) 428,treatment:nact,type of chemo:carbo/taxol	0.745341594591487	MSKCC- Snyder- P01-01		120.0	
TCAGGAGACACAGCACGGTATTTCTGTGCCAGCAGCTCGGGACTCCGGGGCGAGACCCAGTACTTCGGGCCA	CASSSGLRGETQYF	In	VDJ	1	22	0.003014937645607784	0.004032997250229147	42	TCRBV21	TCRBV21-or09_02	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-05	01	5	0	10	5	2	7	24	36	44	38	51						01,02								CASSSGLRGETQYF+TCRBV21-or09_02+TCRBJ02-05	TCRBV21-or09_02*01	TCRBD02-01	TCRBJ02-05*01	5660A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment				161	120	39	1	0	128	98	29	1	0	7297	5455	1791	51	0	0.0534780733	6.26096773	0.0522329435	6.63436937				479	0.25057435	0.0612282306	0.0457722358	v2	Human-TCRB-PD2x	Published	08/10/2016 11:24:40	07/05/2016 03:54:28	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment,os censored status (0 = alive, 1=dead):os censored status (0 = alive, 1=dead) 1,overall survival (days):overall survival (days) 1526,pfs censored status (0 = pf, 1=progressed):pfs censored status (0 = pf, 1=progressed) 1,progression free survival (days):progression free survival (days) 428,treatment:nact,type of chemo:carbo/taxol	0.745341594591487	MSKCC- Snyder- P01-01		120.0	
TCAGGAGACACAGCACGGTATTTCTGTGCCAGCAGCGTAGGTTGGCATCCACCTCCCGAGCAGTACTTCGGGCCG	CASSVGWHPPPEQYF	In	VDJ	1	20	0.0027408524050979853	0.0036663611365719525	45	TCRBV21	TCRBV21-or09_02	01				TCRBJ02	TCRBJ02-07	01	5	5	4	6	2	15	24	36	41	38	56				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSVGWHPPPEQYF+TCRBV21-or09_02+TCRBJ02-07	TCRBV21-or09_02*01		TCRBJ02-07*01	5660A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment				161	120	39	1	0	128	98	29	1	0	7297	5455	1791	51	0	0.0534780733	6.26096773	0.0522329435	6.63436937				479	0.25057435	0.0612282306	0.0457722358	v2	Human-TCRB-PD2x	Published	08/10/2016 11:24:40	07/05/2016 03:54:28	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment,os censored status (0 = alive, 1=dead):os censored status (0 = alive, 1=dead) 1,overall survival (days):overall survival (days) 1526,pfs censored status (0 = pf, 1=progressed):pfs censored status (0 = pf, 1=progressed) 1,progression free survival (days):progression free survival (days) 428,treatment:nact,type of chemo:carbo/taxol	0.745341594591487	MSKCC- Snyder- P01-01		120.0	
GACTCGGCCATGTATCGCTGTGCCAGCAGCTTAGCAGGGATGAACACTGAAGCTTTCTTTGGACAA	CASSLAGMNTEAFF	In	VDJ	1	42	0.00575579005070577	0.0076993583868011	42	TCRBV07	TCRBV07-06	01				TCRBJ01	TCRBJ01-01	01	0	0	8	0	1	0	18	35	-1	36	40				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSLAGMNTEAFF+TCRBV07-06+TCRBJ01-01	TCRBV07-06*01		TCRBJ01-01*01	5660A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment				161	120	39	1	0	128	98	29	1	0	7297	5455	1791	51	0	0.0534780733	6.26096773	0.0522329435	6.63436937				479	0.25057435	0.0612282306	0.0457722358	v2	Human-TCRB-PD2x	Published	08/10/2016 11:24:40	07/05/2016 03:54:28	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment,os censored status (0 = alive, 1=dead):os censored status (0 = alive, 1=dead) 1,overall survival (days):overall survival (days) 1526,pfs censored status (0 = pf, 1=progressed):pfs censored status (0 = pf, 1=progressed) 1,progression free survival (days):progression free survival (days) 428,treatment:nact,type of chemo:carbo/taxol	0.745341594591487	MSKCC- Snyder- P01-01		120.0	
GACTCGGCCATGTATCGCTGTGCCAGCAGCTCTACCTGGGGACCCCGGAATGAGCAGTTCTTCGGGCCA	CASSSTWGPRNEQFF	In	VDJ	1	24	0.0032890228861175825	0.004399633363886343	45	TCRBV07	TCRBV07-06	01				TCRBJ02	TCRBJ02-01	01	4	0	7	7	7	5	18	31	43	38	48				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSSTWGPRNEQFF+TCRBV07-06+TCRBJ02-01	TCRBV07-06*01		TCRBJ02-01*01	5660A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment				161	120	39	1	0	128	98	29	1	0	7297	5455	1791	51	0	0.0534780733	6.26096773	0.0522329435	6.63436937				479	0.25057435	0.0612282306	0.0457722358	v2	Human-TCRB-PD2x	Published	08/10/2016 11:24:40	07/05/2016 03:54:28	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment,os censored status (0 = alive, 1=dead):os censored status (0 = alive, 1=dead) 1,overall survival (days):overall survival (days) 1526,pfs censored status (0 = pf, 1=progressed):pfs censored status (0 = pf, 1=progressed) 1,progression free survival (days):progression free survival (days) 428,treatment:nact,type of chemo:carbo/taxol	0.745341594591487	MSKCC- Snyder- P01-01		120.0	
CGACTCGGCTGTGTATCTCTGTGCCAGCAGCTTGGCGGTGACGGGCCTCTACAATGAGCAGTTCTTCGGGCCA	CASSLAVTGLYNEQFF	In	VDJ	1	39	0.005344662189941072	0.007149404216315307	48	TCRBV07	TCRBV07-05	01				TCRBJ02	TCRBJ02-01	01	2	8	0	3	9	2	19	33	46	42	48				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSLAVTGLYNEQFF+TCRBV07-05+TCRBJ02-01	TCRBV07-05*01		TCRBJ02-01*01	5660A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment				161	120	39	1	0	128	98	29	1	0	7297	5455	1791	51	0	0.0534780733	6.26096773	0.0522329435	6.63436937				479	0.25057435	0.0612282306	0.0457722358	v2	Human-TCRB-PD2x	Published	08/10/2016 11:24:40	07/05/2016 03:54:28	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment,os censored status (0 = alive, 1=dead):os censored status (0 = alive, 1=dead) 1,overall survival (days):overall survival (days) 1526,pfs censored status (0 = pf, 1=progressed):pfs censored status (0 = pf, 1=progressed) 1,progression free survival (days):progression free survival (days) 428,treatment:nact,type of chemo:carbo/taxol	0.745341594591487	MSKCC- Snyder- P01-01		120.0	
TYCTCAGTGACTCTGGCTTCTATCTCTGTGCCTGGGATATCTCGGGACTCCCCGGCGAGCAGTACTTCGGGCCG	CAWDISGLPGEQYF	In	VDJ	3	171	0.023434288063587775	0.03134738771769019	42	TCRBV30	TCRBV30-01	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-07	01	5	0	10	6	8	6	26	35	49	43	55			unresolved			01,02							Vb 20	CAWDISGLPGEQYF+TCRBV30-01+TCRBJ02-07	TCRBV30-01*01	TCRBD02-01	TCRBJ02-07*01	5660A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment				161	120	39	1	0	128	98	29	1	0	7297	5455	1791	51	0	0.0534780733	6.26096773	0.0522329435	6.63436937				479	0.25057435	0.0612282306	0.0457722358	v2	Human-TCRB-PD2x	Published	08/10/2016 11:24:40	07/05/2016 03:54:28	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment,os censored status (0 = alive, 1=dead):os censored status (0 = alive, 1=dead) 1,overall survival (days):overall survival (days) 1526,pfs censored status (0 = pf, 1=progressed):pfs censored status (0 = pf, 1=progressed) 1,progression free survival (days):progression free survival (days) 428,treatment:nact,type of chemo:carbo/taxol	0.745341594591487	MSKCC- Snyder- P01-01		120.0	
TYCTCAGTGACTCTGGCTTCTATCTCTGTGCCTGGAGTCAGGAACCAAGGCTCCCCCTCGAGCAGTACTTCGGGCCG	CAWSQEPRLPLEQYF	In	VDJ	1	58	0.007948471974784158	0.010632447296058662	45	TCRBV30	TCRBV30-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	2	4	4	6	0	16	26	-1	42	38	58			unresolved										Vb 20	CAWSQEPRLPLEQYF+TCRBV30-01+TCRBJ02-07	TCRBV30-01*01	TCRBD01-01*01	TCRBJ02-07*01	5660A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment				161	120	39	1	0	128	98	29	1	0	7297	5455	1791	51	0	0.0534780733	6.26096773	0.0522329435	6.63436937				479	0.25057435	0.0612282306	0.0457722358	v2	Human-TCRB-PD2x	Published	08/10/2016 11:24:40	07/05/2016 03:54:28	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment,os censored status (0 = alive, 1=dead):os censored status (0 = alive, 1=dead) 1,overall survival (days):overall survival (days) 1526,pfs censored status (0 = pf, 1=progressed):pfs censored status (0 = pf, 1=progressed) 1,progression free survival (days):progression free survival (days) 428,treatment:nact,type of chemo:carbo/taxol	0.745341594591487	MSKCC- Snyder- P01-01		120.0	
TTCTCAGTGACTCTGGCTTCTATCTCTGTGCCTGGAGTGACGGGGGCCGCGGGAGCACAGATACGCAGTATTTTGGCCCA	CAWSDGGRGSTDTQYF	In	VDJ	1	50	0.006852131012744964	0.00916590284142988	48	TCRBV30	TCRBV30-01	01				TCRBJ02	TCRBJ02-03	01	1	6	0	0	2	6	26	39	47	41	53				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 20	CAWSDGGRGSTDTQYF+TCRBV30-01+TCRBJ02-03	TCRBV30-01*01		TCRBJ02-03*01	5660A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment				161	120	39	1	0	128	98	29	1	0	7297	5455	1791	51	0	0.0534780733	6.26096773	0.0522329435	6.63436937				479	0.25057435	0.0612282306	0.0457722358	v2	Human-TCRB-PD2x	Published	08/10/2016 11:24:40	07/05/2016 03:54:28	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment,os censored status (0 = alive, 1=dead):os censored status (0 = alive, 1=dead) 1,overall survival (days):overall survival (days) 1526,pfs censored status (0 = pf, 1=progressed):pfs censored status (0 = pf, 1=progressed) 1,progression free survival (days):progression free survival (days) 428,treatment:nact,type of chemo:carbo/taxol	0.745341594591487	MSKCC- Snyder- P01-01		120.0	
TTCTCAGTGACTCTGGCTTCTATCTCTGTGCCTGCAATAAGGCTAGCGGGAGAGATGAGCAGTTCTTCGGGCCA	CACNKASGRDEQFF	In	VDJ	1	40	0.005481704810195971	0.007332722273143905	42	TCRBV30	TCRBV30-01	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	6	4	2	8	8	2	26	34	52	42	54													Vb 20	CACNKASGRDEQFF+TCRBV30-01+TCRBJ02-01	TCRBV30-01*01	TCRBD02-01*02	TCRBJ02-01*01	5660A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment				161	120	39	1	0	128	98	29	1	0	7297	5455	1791	51	0	0.0534780733	6.26096773	0.0522329435	6.63436937				479	0.25057435	0.0612282306	0.0457722358	v2	Human-TCRB-PD2x	Published	08/10/2016 11:24:40	07/05/2016 03:54:28	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment,os censored status (0 = alive, 1=dead):os censored status (0 = alive, 1=dead) 1,overall survival (days):overall survival (days) 1526,pfs censored status (0 = pf, 1=progressed):pfs censored status (0 = pf, 1=progressed) 1,progression free survival (days):progression free survival (days) 428,treatment:nact,type of chemo:carbo/taxol	0.745341594591487	MSKCC- Snyder- P01-01		120.0	
TTCTCAGTGACTCTGGCTTCTATCTCTGTGCCTGGAGTCTTGCGGGGGGGGTCGAGCAGTACTTCGGGCCG	CAWSLAGGVEQYF	In	VDJ	1	32	0.004385363848156776	0.005866177818515124	39	TCRBV30	TCRBV30-01	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-07	01	2	7	0	6	3	2	26	38	50	41	52													Vb 20	CAWSLAGGVEQYF+TCRBV30-01+TCRBJ02-07	TCRBV30-01*01	TCRBD02-01*01	TCRBJ02-07*01	5660A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment				161	120	39	1	0	128	98	29	1	0	7297	5455	1791	51	0	0.0534780733	6.26096773	0.0522329435	6.63436937				479	0.25057435	0.0612282306	0.0457722358	v2	Human-TCRB-PD2x	Published	08/10/2016 11:24:40	07/05/2016 03:54:28	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment,os censored status (0 = alive, 1=dead):os censored status (0 = alive, 1=dead) 1,overall survival (days):overall survival (days) 1526,pfs censored status (0 = pf, 1=progressed):pfs censored status (0 = pf, 1=progressed) 1,progression free survival (days):progression free survival (days) 428,treatment:nact,type of chemo:carbo/taxol	0.745341594591487	MSKCC- Snyder- P01-01		120.0	
TTCTCAGTGACTCTGGCTTCTATCTCTGTGCCTGGGTTTTAGGGGGCACTGAAGCTTTCTTTGGACAA	CAWVLGGTEAFF	In	VDJ	1	28	0.0038371933671371796	0.0051329055912007334	36	TCRBV30	TCRBV30-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	5	5	1	4	5	0	26	35	-1	40	46													Vb 20	CAWVLGGTEAFF+TCRBV30-01+TCRBJ01-01	TCRBV30-01*01	TCRBD01-01*01	TCRBJ01-01*01	5660A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment				161	120	39	1	0	128	98	29	1	0	7297	5455	1791	51	0	0.0534780733	6.26096773	0.0522329435	6.63436937				479	0.25057435	0.0612282306	0.0457722358	v2	Human-TCRB-PD2x	Published	08/10/2016 11:24:40	07/05/2016 03:54:28	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment,os censored status (0 = alive, 1=dead):os censored status (0 = alive, 1=dead) 1,overall survival (days):overall survival (days) 1526,pfs censored status (0 = pf, 1=progressed):pfs censored status (0 = pf, 1=progressed) 1,progression free survival (days):progression free survival (days) 428,treatment:nact,type of chemo:carbo/taxol	0.745341594591487	MSKCC- Snyder- P01-01		120.0	
TCCTCAGTGACTCTGGCTTCTATCTCTGTGCCTGGAGAAATAGCGGGAAGCACAGATACGCAGTATTTTGGCCCA		Out	VDJ	1	21	0.002877895025352885		43	TCRBV30	TCRBV30-01	02	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-03	01	3	5	3	0	3	0	26	37	-1	40	48													Vb 20	X+TCRBV30-01+TCRBJ02-03	TCRBV30-01*02	TCRBD02-01*02	TCRBJ02-03*01	5660A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment				161	120	39	1	0	128	98	29	1	0	7297	5455	1791	51	0	0.0534780733	6.26096773	0.0522329435	6.63436937				479	0.25057435	0.0612282306	0.0457722358	v2	Human-TCRB-PD2x	Published	08/10/2016 11:24:40	07/05/2016 03:54:28	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment,os censored status (0 = alive, 1=dead):os censored status (0 = alive, 1=dead) 1,overall survival (days):overall survival (days) 1526,pfs censored status (0 = pf, 1=progressed):pfs censored status (0 = pf, 1=progressed) 1,progression free survival (days):progression free survival (days) 428,treatment:nact,type of chemo:carbo/taxol	0.745341594591487	MSKCC- Snyder- P01-01		120.0	
AAGAAGACTCAGCTGCGTATCTCTGCACCAGCAGGGAGAGTCGGGCCAACGTCCTGACTTTCGGGGCC	CTSRESRANVLTF	In	VDJ	1	76	0.010415239139372345	0.013932172318973418	39	TCRBV01	TCRBV01-01	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-06	01	6	10	2	5	0	4	23	-1	38	34	42														CTSRESRANVLTF+TCRBV01-01+TCRBJ02-06	TCRBV01-01*01	TCRBD02-01*02	TCRBJ02-06*01	5660A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment				161	120	39	1	0	128	98	29	1	0	7297	5455	1791	51	0	0.0534780733	6.26096773	0.0522329435	6.63436937				479	0.25057435	0.0612282306	0.0457722358	v2	Human-TCRB-PD2x	Published	08/10/2016 11:24:40	07/05/2016 03:54:28	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment,os censored status (0 = alive, 1=dead):os censored status (0 = alive, 1=dead) 1,overall survival (days):overall survival (days) 1526,pfs censored status (0 = pf, 1=progressed):pfs censored status (0 = pf, 1=progressed) 1,progression free survival (days):progression free survival (days) 428,treatment:nact,type of chemo:carbo/taxol	0.745341594591487	MSKCC- Snyder- P01-01		120.0	
AAGAAGACTCAGCTGCGTATCTCTGCGCCAGCGGGGTTGACAGGGCCAGCGAGCAGTACTTCGGGCCG	CASGVDRASEQYF	In	VDJ	1	40	0.005481704810195971	0.007332722273143905	39	TCRBV01	TCRBV01-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	8	2	3	6	6	4	23	32	45	38	49														CASGVDRASEQYF+TCRBV01-01+TCRBJ02-07	TCRBV01-01*01	TCRBD01-01*01	TCRBJ02-07*01	5660A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment				161	120	39	1	0	128	98	29	1	0	7297	5455	1791	51	0	0.0534780733	6.26096773	0.0522329435	6.63436937				479	0.25057435	0.0612282306	0.0457722358	v2	Human-TCRB-PD2x	Published	08/10/2016 11:24:40	07/05/2016 03:54:28	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment,os censored status (0 = alive, 1=dead):os censored status (0 = alive, 1=dead) 1,overall survival (days):overall survival (days) 1526,pfs censored status (0 = pf, 1=progressed):pfs censored status (0 = pf, 1=progressed) 1,progression free survival (days):progression free survival (days) 428,treatment:nact,type of chemo:carbo/taxol	0.745341594591487	MSKCC- Snyder- P01-01		120.0	
AAGAAGACTCAGCTGCGTATCTCTGCGCCAGCAGCCAAGAATTTATGGGGGGCACCGGGGAGCTGTTTTTTGGAGAA	CASSQEFMGGTGELFF	In	VDJ	1	35	0.004796491708921474	0.006416131989000917	48	TCRBV01	TCRBV01-01	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-02	01	0	9	1	4	6	0	23	40	-1	46	52														CASSQEFMGGTGELFF+TCRBV01-01+TCRBJ02-02	TCRBV01-01*01	TCRBD02-01*01	TCRBJ02-02*01	5660A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment				161	120	39	1	0	128	98	29	1	0	7297	5455	1791	51	0	0.0534780733	6.26096773	0.0522329435	6.63436937				479	0.25057435	0.0612282306	0.0457722358	v2	Human-TCRB-PD2x	Published	08/10/2016 11:24:40	07/05/2016 03:54:28	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment,os censored status (0 = alive, 1=dead):os censored status (0 = alive, 1=dead) 1,overall survival (days):overall survival (days) 1526,pfs censored status (0 = pf, 1=progressed):pfs censored status (0 = pf, 1=progressed) 1,progression free survival (days):progression free survival (days) 428,treatment:nact,type of chemo:carbo/taxol	0.745341594591487	MSKCC- Snyder- P01-01		120.0	
GGACTCGGCCCTTTATCTTTGCGCCAGCAGCCCCGTCGACAGATACAATGAGCAGTTCTTCGGGCCA	CASSPVDRYNEQFF	In	VDJ	1	36	0.0049335343291763735	0.006599450045829514	42	TCRBV05	TCRBV05-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	4	2	5	4	6	1	19	31	42	37	43													Vb 5.1	CASSPVDRYNEQFF+TCRBV05-01+TCRBJ02-01	TCRBV05-01*01	TCRBD01-01*01	TCRBJ02-01*01	5660A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment				161	120	39	1	0	128	98	29	1	0	7297	5455	1791	51	0	0.0534780733	6.26096773	0.0522329435	6.63436937				479	0.25057435	0.0612282306	0.0457722358	v2	Human-TCRB-PD2x	Published	08/10/2016 11:24:40	07/05/2016 03:54:28	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment,os censored status (0 = alive, 1=dead):os censored status (0 = alive, 1=dead) 1,overall survival (days):overall survival (days) 1526,pfs censored status (0 = pf, 1=progressed):pfs censored status (0 = pf, 1=progressed) 1,progression free survival (days):progression free survival (days) 428,treatment:nact,type of chemo:carbo/taxol	0.745341594591487	MSKCC- Snyder- P01-01		120.0	
GAGGGACTCAGCCGTGTATCTCTACAGTAGCACGCTGCTTTTCTGGGAAAGACCTATGGCTACACCTTCGGTTCG		Out	VDJ	1	55	0.00753734411401946		47	TCRBV17	TCRBV17-01	01				TCRBJ01	TCRBJ01-02	01	5	0	8	4	13	5	22	31	48	44	53				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									X+TCRBV17-01+TCRBJ01-02	TCRBV17-01*01		TCRBJ01-02*01	5660A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment				161	120	39	1	0	128	98	29	1	0	7297	5455	1791	51	0	0.0534780733	6.26096773	0.0522329435	6.63436937				479	0.25057435	0.0612282306	0.0457722358	v2	Human-TCRB-PD2x	Published	08/10/2016 11:24:40	07/05/2016 03:54:28	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment,os censored status (0 = alive, 1=dead):os censored status (0 = alive, 1=dead) 1,overall survival (days):overall survival (days) 1526,pfs censored status (0 = pf, 1=progressed):pfs censored status (0 = pf, 1=progressed) 1,progression free survival (days):progression free survival (days) 428,treatment:nact,type of chemo:carbo/taxol	0.745341594591487	MSKCC- Snyder- P01-01		120.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTCCGTAGACAGCTGAACACTGAAGCTTTCTTTGGACAA		Out	VDJ	1	44	0.006029875291215568		43	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	5	2	5	0	5	1	25	37	47	42	48													Vb 3	X+TCRBV28-01+TCRBJ01-01	TCRBV28-01*01	TCRBD01-01*01	TCRBJ01-01*01	5660A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment				161	120	39	1	0	128	98	29	1	0	7297	5455	1791	51	0	0.0534780733	6.26096773	0.0522329435	6.63436937				479	0.25057435	0.0612282306	0.0457722358	v2	Human-TCRB-PD2x	Published	08/10/2016 11:24:40	07/05/2016 03:54:28	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment,os censored status (0 = alive, 1=dead):os censored status (0 = alive, 1=dead) 1,overall survival (days):overall survival (days) 1526,pfs censored status (0 = pf, 1=progressed):pfs censored status (0 = pf, 1=progressed) 1,progression free survival (days):progression free survival (days) 428,treatment:nact,type of chemo:carbo/taxol	0.745341594591487	MSKCC- Snyder- P01-01		120.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTTTATTAGGGGGGCCCCTTTACGAGCAGTACTTCGGGCCG	CASSLLGGPLYEQYF	In	VDJ	1	18	0.0024667671645881867	0.003299725022914757	45	TCRBV28	TCRBV28-01	01				TCRBJ02	TCRBJ02-07	01	1	5	1	4	1	7	25	41	48	42	55				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 3	CASSLLGGPLYEQYF+TCRBV28-01+TCRBJ02-07	TCRBV28-01*01		TCRBJ02-07*01	5660A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment				161	120	39	1	0	128	98	29	1	0	7297	5455	1791	51	0	0.0534780733	6.26096773	0.0522329435	6.63436937				479	0.25057435	0.0612282306	0.0457722358	v2	Human-TCRB-PD2x	Published	08/10/2016 11:24:40	07/05/2016 03:54:28	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment,os censored status (0 = alive, 1=dead):os censored status (0 = alive, 1=dead) 1,overall survival (days):overall survival (days) 1526,pfs censored status (0 = pf, 1=progressed):pfs censored status (0 = pf, 1=progressed) 1,progression free survival (days):progression free survival (days) 428,treatment:nact,type of chemo:carbo/taxol	0.745341594591487	MSKCC- Snyder- P01-01		120.0	
GCTCCCAGACATCTGTGTATTTCTGCGCCAGCAGTGACATGTCAGATACGCAGTATTTTGGCCCA	CASSDMSDTQYF	In	VDJ	1	51	0.006989173632999863	0.009349220898258478	36	TCRBV10	TCRBV10-02	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	3	4	6	4	0	3	23	-1	39	37	42													Vb 12	CASSDMSDTQYF+TCRBV10-02+TCRBJ02-03	TCRBV10-02*01	TCRBD01-01*01	TCRBJ02-03*01	5660A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment				161	120	39	1	0	128	98	29	1	0	7297	5455	1791	51	0	0.0534780733	6.26096773	0.0522329435	6.63436937				479	0.25057435	0.0612282306	0.0457722358	v2	Human-TCRB-PD2x	Published	08/10/2016 11:24:40	07/05/2016 03:54:28	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment,os censored status (0 = alive, 1=dead):os censored status (0 = alive, 1=dead) 1,overall survival (days):overall survival (days) 1526,pfs censored status (0 = pf, 1=progressed):pfs censored status (0 = pf, 1=progressed) 1,progression free survival (days):progression free survival (days) 428,treatment:nact,type of chemo:carbo/taxol	0.745341594591487	MSKCC- Snyder- P01-01		120.0	
GCTCCCAGACATCTGTGTATTTCTGCGCCAGCAGTGAAGACGGCATGAACACTGAAGCTTTCTTTGGACAA	CASSEDGMNTEAFF	In	VDJ	1	31	0.004248321227901877	0.0056828597616865265	42	TCRBV10	TCRBV10-02	01				TCRBJ01	TCRBJ01-01	01	3	2	7	0	1	4	23	37	41	38	45				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 12	CASSEDGMNTEAFF+TCRBV10-02+TCRBJ01-01	TCRBV10-02*01		TCRBJ01-01*01	5660A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment				161	120	39	1	0	128	98	29	1	0	7297	5455	1791	51	0	0.0534780733	6.26096773	0.0522329435	6.63436937				479	0.25057435	0.0612282306	0.0457722358	v2	Human-TCRB-PD2x	Published	08/10/2016 11:24:40	07/05/2016 03:54:28	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment,os censored status (0 = alive, 1=dead):os censored status (0 = alive, 1=dead) 1,overall survival (days):overall survival (days) 1526,pfs censored status (0 = pf, 1=progressed):pfs censored status (0 = pf, 1=progressed) 1,progression free survival (days):progression free survival (days) 428,treatment:nact,type of chemo:carbo/taxol	0.745341594591487	MSKCC- Snyder- P01-01		120.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCATCAGTGAGCAGGAGGCTAACTATGGCTACACCTTCGGTTCG	CAISEQEANYGYTF	In	VDJ	3	179	0.02453062902562697	0.032813932172318976	42	TCRBV10	TCRBV10-03	01	TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-02	01	2	10	1	0	2	0	23	38	-1	40	45													Vb 12	CAISEQEANYGYTF+TCRBV10-03+TCRBJ01-02	TCRBV10-03*01	TCRBD02-01*02	TCRBJ01-02*01	5660A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment				161	120	39	1	0	128	98	29	1	0	7297	5455	1791	51	0	0.0534780733	6.26096773	0.0522329435	6.63436937				479	0.25057435	0.0612282306	0.0457722358	v2	Human-TCRB-PD2x	Published	08/10/2016 11:24:40	07/05/2016 03:54:28	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment,os censored status (0 = alive, 1=dead):os censored status (0 = alive, 1=dead) 1,overall survival (days):overall survival (days) 1526,pfs censored status (0 = pf, 1=progressed):pfs censored status (0 = pf, 1=progressed) 1,progression free survival (days):progression free survival (days) 428,treatment:nact,type of chemo:carbo/taxol	0.745341594591487	MSKCC- Snyder- P01-01		120.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCATCAGTGAGAGAGAGCTCCGGGGGGGTGAGCAGTACTTCGGGCCG	CAISERELRGGEQYF	In	VDJ	1	21	0.002877895025352885	0.00384967919340055	45	TCRBV10	TCRBV10-03	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-07	01	2	8	0	7	9	1	23	38	55	47	56													Vb 12	CAISERELRGGEQYF+TCRBV10-03+TCRBJ02-07	TCRBV10-03*01	TCRBD02-01*01	TCRBJ02-07*01	5660A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment				161	120	39	1	0	128	98	29	1	0	7297	5455	1791	51	0	0.0534780733	6.26096773	0.0522329435	6.63436937				479	0.25057435	0.0612282306	0.0457722358	v2	Human-TCRB-PD2x	Published	08/10/2016 11:24:40	07/05/2016 03:54:28	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment,os censored status (0 = alive, 1=dead):os censored status (0 = alive, 1=dead) 1,overall survival (days):overall survival (days) 1526,pfs censored status (0 = pf, 1=progressed):pfs censored status (0 = pf, 1=progressed) 1,progression free survival (days):progression free survival (days) 428,treatment:nact,type of chemo:carbo/taxol	0.745341594591487	MSKCC- Snyder- P01-01		120.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTATATGGCCTAAAGAAAAACTGTTTTTTGGCAGT	CASSIWPKEKLFF	In	VDJ	4	208	0.02850486501301905	0.0381301558203483	39	TCRBV19	TCRBV19-01					TCRBJ01	TCRBJ01-04	01	2	9	0	8	1	5	27	42	46	43	51			01,02	TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 17	CASSIWPKEKLFF+TCRBV19-01+TCRBJ01-04	TCRBV19-01		TCRBJ01-04*01	5660A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment				161	120	39	1	0	128	98	29	1	0	7297	5455	1791	51	0	0.0534780733	6.26096773	0.0522329435	6.63436937				479	0.25057435	0.0612282306	0.0457722358	v2	Human-TCRB-PD2x	Published	08/10/2016 11:24:40	07/05/2016 03:54:28	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment,os censored status (0 = alive, 1=dead):os censored status (0 = alive, 1=dead) 1,overall survival (days):overall survival (days) 1526,pfs censored status (0 = pf, 1=progressed):pfs censored status (0 = pf, 1=progressed) 1,progression free survival (days):progression free survival (days) 428,treatment:nact,type of chemo:carbo/taxol	0.745341594591487	MSKCC- Snyder- P01-01		120.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCATCCTCTATACCGGGAGCAGTACTTCGGGCCG		Out	VDJ	3	143	0.019597094696450598		32	TCRBV19	TCRBV19-01		TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-07	01	10	4	9	7	4	6	27	34	41	38	47			01,02			01,02							Vb 17	X+TCRBV19-01+TCRBJ02-07	TCRBV19-01	TCRBD02-01	TCRBJ02-07*01	5660A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment				161	120	39	1	0	128	98	29	1	0	7297	5455	1791	51	0	0.0534780733	6.26096773	0.0522329435	6.63436937				479	0.25057435	0.0612282306	0.0457722358	v2	Human-TCRB-PD2x	Published	08/10/2016 11:24:40	07/05/2016 03:54:28	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment,os censored status (0 = alive, 1=dead):os censored status (0 = alive, 1=dead) 1,overall survival (days):overall survival (days) 1526,pfs censored status (0 = pf, 1=progressed):pfs censored status (0 = pf, 1=progressed) 1,progression free survival (days):progression free survival (days) 428,treatment:nact,type of chemo:carbo/taxol	0.745341594591487	MSKCC- Snyder- P01-01		120.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTATCTTAGGACAGGGGGCCTCGAACACTGAAGCTTTCTTTGGACAA	CASSILGQGASNTEAFF	In	VDJ	2	105	0.014389475126764424	0.01924839596700275	51	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	3	1	0	1	4	3	27	41	56	45	59			01,02										Vb 17	CASSILGQGASNTEAFF+TCRBV19-01+TCRBJ01-01	TCRBV19-01	TCRBD01-01*01	TCRBJ01-01*01	5660A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment				161	120	39	1	0	128	98	29	1	0	7297	5455	1791	51	0	0.0534780733	6.26096773	0.0522329435	6.63436937				479	0.25057435	0.0612282306	0.0457722358	v2	Human-TCRB-PD2x	Published	08/10/2016 11:24:40	07/05/2016 03:54:28	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment,os censored status (0 = alive, 1=dead):os censored status (0 = alive, 1=dead) 1,overall survival (days):overall survival (days) 1526,pfs censored status (0 = pf, 1=progressed):pfs censored status (0 = pf, 1=progressed) 1,progression free survival (days):progression free survival (days) 428,treatment:nact,type of chemo:carbo/taxol	0.745341594591487	MSKCC- Snyder- P01-01		120.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTCGATCACTAGCGGCCACAGGCGATGAGCAGTTCTTCGGGCCA	CASRSLAATGDEQFF	In	VDJ	1	80	0.010963409620391941	0.01466544454628781	45	TCRBV19	TCRBV19-01		TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	8	3	5	8	5	9	27	36	49	41	58			01,02			01,02							Vb 17	CASRSLAATGDEQFF+TCRBV19-01+TCRBJ02-01	TCRBV19-01	TCRBD02-01	TCRBJ02-01*01	5660A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment				161	120	39	1	0	128	98	29	1	0	7297	5455	1791	51	0	0.0534780733	6.26096773	0.0522329435	6.63436937				479	0.25057435	0.0612282306	0.0457722358	v2	Human-TCRB-PD2x	Published	08/10/2016 11:24:40	07/05/2016 03:54:28	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment,os censored status (0 = alive, 1=dead):os censored status (0 = alive, 1=dead) 1,overall survival (days):overall survival (days) 1526,pfs censored status (0 = pf, 1=progressed):pfs censored status (0 = pf, 1=progressed) 1,progression free survival (days):progression free survival (days) 428,treatment:nact,type of chemo:carbo/taxol	0.745341594591487	MSKCC- Snyder- P01-01		120.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTATCCGACAGGGATCAGATACGCAGTATTTTGGCCCA	CASSIRQGSDTQYF	In	VDJ	1	79	0.010826367000137043	0.014482126489459212	42	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	3	2	3	4	2	2	27	41	50	43	52			01,02										Vb 17	CASSIRQGSDTQYF+TCRBV19-01+TCRBJ02-03	TCRBV19-01	TCRBD01-01*01	TCRBJ02-03*01	5660A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment				161	120	39	1	0	128	98	29	1	0	7297	5455	1791	51	0	0.0534780733	6.26096773	0.0522329435	6.63436937				479	0.25057435	0.0612282306	0.0457722358	v2	Human-TCRB-PD2x	Published	08/10/2016 11:24:40	07/05/2016 03:54:28	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment,os censored status (0 = alive, 1=dead):os censored status (0 = alive, 1=dead) 1,overall survival (days):overall survival (days) 1526,pfs censored status (0 = pf, 1=progressed):pfs censored status (0 = pf, 1=progressed) 1,progression free survival (days):progression free survival (days) 428,treatment:nact,type of chemo:carbo/taxol	0.745341594591487	MSKCC- Snyder- P01-01		120.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTATACACAACCAGGGAGATACGCAGTATTTTGGCCCA	CASSIHNQGDTQYF	In	VDJ	1	76	0.010415239139372345	0.013932172318973418	42	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	2	4	3	5	6	0	27	42	-1	48	53			01,02										Vb 17	CASSIHNQGDTQYF+TCRBV19-01+TCRBJ02-03	TCRBV19-01	TCRBD01-01*01	TCRBJ02-03*01	5660A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment				161	120	39	1	0	128	98	29	1	0	7297	5455	1791	51	0	0.0534780733	6.26096773	0.0522329435	6.63436937				479	0.25057435	0.0612282306	0.0457722358	v2	Human-TCRB-PD2x	Published	08/10/2016 11:24:40	07/05/2016 03:54:28	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment,os censored status (0 = alive, 1=dead):os censored status (0 = alive, 1=dead) 1,overall survival (days):overall survival (days) 1526,pfs censored status (0 = pf, 1=progressed):pfs censored status (0 = pf, 1=progressed) 1,progression free survival (days):progression free survival (days) 428,treatment:nact,type of chemo:carbo/taxol	0.745341594591487	MSKCC- Snyder- P01-01		120.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAAGGAACTAGCGCATCAATTTGAGCAGTTCTTCGGGCCA	CASKELAHQFEQFF	In	VDJ	1	76	0.010415239139372345	0.013932172318973418	42	TCRBV19	TCRBV19-01		TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	7	3	6	9	4	8	27	37	48	41	56			01,02			01,02							Vb 17	CASKELAHQFEQFF+TCRBV19-01+TCRBJ02-01	TCRBV19-01	TCRBD02-01	TCRBJ02-01*01	5660A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment				161	120	39	1	0	128	98	29	1	0	7297	5455	1791	51	0	0.0534780733	6.26096773	0.0522329435	6.63436937				479	0.25057435	0.0612282306	0.0457722358	v2	Human-TCRB-PD2x	Published	08/10/2016 11:24:40	07/05/2016 03:54:28	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment,os censored status (0 = alive, 1=dead):os censored status (0 = alive, 1=dead) 1,overall survival (days):overall survival (days) 1526,pfs censored status (0 = pf, 1=progressed):pfs censored status (0 = pf, 1=progressed) 1,progression free survival (days):progression free survival (days) 428,treatment:nact,type of chemo:carbo/taxol	0.745341594591487	MSKCC- Snyder- P01-01		120.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTAATCTGGGTGAGCAGTACTTCGGGCCG	CASSNLGEQYF	In	VDJ	1	41	0.005618747430450871	0.007516040329972502	33	TCRBV19	TCRBV19-01					TCRBJ02	TCRBJ02-07	01	4	0	9	7	4	1	27	40	47	44	48			01,02	TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 17	CASSNLGEQYF+TCRBV19-01+TCRBJ02-07	TCRBV19-01		TCRBJ02-07*01	5660A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment				161	120	39	1	0	128	98	29	1	0	7297	5455	1791	51	0	0.0534780733	6.26096773	0.0522329435	6.63436937				479	0.25057435	0.0612282306	0.0457722358	v2	Human-TCRB-PD2x	Published	08/10/2016 11:24:40	07/05/2016 03:54:28	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment,os censored status (0 = alive, 1=dead):os censored status (0 = alive, 1=dead) 1,overall survival (days):overall survival (days) 1526,pfs censored status (0 = pf, 1=progressed):pfs censored status (0 = pf, 1=progressed) 1,progression free survival (days):progression free survival (days) 428,treatment:nact,type of chemo:carbo/taxol	0.745341594591487	MSKCC- Snyder- P01-01		120.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTATTGTTGGGGCAGCCAATGAGCAGTTCTTCGGGCCA	CASSIVGAANEQFF	In	VDJ	1	36	0.0049335343291763735	0.006599450045829514	42	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	3	7	0	6	4	3	27	41	50	45	53			01,02										Vb 17	CASSIVGAANEQFF+TCRBV19-01+TCRBJ02-01	TCRBV19-01	TCRBD01-01*01	TCRBJ02-01*01	5660A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment				161	120	39	1	0	128	98	29	1	0	7297	5455	1791	51	0	0.0534780733	6.26096773	0.0522329435	6.63436937				479	0.25057435	0.0612282306	0.0457722358	v2	Human-TCRB-PD2x	Published	08/10/2016 11:24:40	07/05/2016 03:54:28	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment,os censored status (0 = alive, 1=dead):os censored status (0 = alive, 1=dead) 1,overall survival (days):overall survival (days) 1526,pfs censored status (0 = pf, 1=progressed):pfs censored status (0 = pf, 1=progressed) 1,progression free survival (days):progression free survival (days) 428,treatment:nact,type of chemo:carbo/taxol	0.745341594591487	MSKCC- Snyder- P01-01		120.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTACCACCAGGGCTGGAAACACCATATATTTTGGAGAG	CASTTRAGNTIYF	In	VDJ	1	18	0.0024667671645881867	0.003299725022914757	39	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-03	01	7	4	3	2	4	0	27	37	-1	41	46			01,02										Vb 17	CASTTRAGNTIYF+TCRBV19-01+TCRBJ01-03	TCRBV19-01	TCRBD01-01*01	TCRBJ01-03*01	5660A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment				161	120	39	1	0	128	98	29	1	0	7297	5455	1791	51	0	0.0534780733	6.26096773	0.0522329435	6.63436937				479	0.25057435	0.0612282306	0.0457722358	v2	Human-TCRB-PD2x	Published	08/10/2016 11:24:40	07/05/2016 03:54:28	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment,os censored status (0 = alive, 1=dead):os censored status (0 = alive, 1=dead) 1,overall survival (days):overall survival (days) 1526,pfs censored status (0 = pf, 1=progressed):pfs censored status (0 = pf, 1=progressed) 1,progression free survival (days):progression free survival (days) 428,treatment:nact,type of chemo:carbo/taxol	0.745341594591487	MSKCC- Snyder- P01-01		120.0	
CCTCACATACCTCTCAGTACCTCTGTGCCAGCCACCTCGGGGGACTCCTACGAGCAGTACTTCGGGCCG		Out	VDJ	1	26	0.003563108126627381		40	TCRBV25	TCRBV25-01	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-07	01	8	8	2	0	5	1	23	32	43	37	44													Vb 11	X+TCRBV25-01+TCRBJ02-07	TCRBV25-01*01	TCRBD02-01*01	TCRBJ02-07*01	5660A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment				161	120	39	1	0	128	98	29	1	0	7297	5455	1791	51	0	0.0534780733	6.26096773	0.0522329435	6.63436937				479	0.25057435	0.0612282306	0.0457722358	v2	Human-TCRB-PD2x	Published	08/10/2016 11:24:40	07/05/2016 03:54:28	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment,os censored status (0 = alive, 1=dead):os censored status (0 = alive, 1=dead) 1,overall survival (days):overall survival (days) 1526,pfs censored status (0 = pf, 1=progressed):pfs censored status (0 = pf, 1=progressed) 1,progression free survival (days):progression free survival (days) 428,treatment:nact,type of chemo:carbo/taxol	0.745341594591487	MSKCC- Snyder- P01-01		120.0	
CCTCACATACCTCTCAGTACCTCTGTGCCAGCAGTATCCCAACCTGGACAAAGTCGGGCCAACGTCCTGACTTTCGGGGCC		Out	VDJ	1	23	0.0031519802658626834		52	TCRBV25	TCRBV25-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-06	01	5	1	6	5	10	5	23	35	50	45	55													Vb 11	X+TCRBV25-01+TCRBJ02-06	TCRBV25-01*01	TCRBD01-01*01	TCRBJ02-06*01	5660A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment				161	120	39	1	0	128	98	29	1	0	7297	5455	1791	51	0	0.0534780733	6.26096773	0.0522329435	6.63436937				479	0.25057435	0.0612282306	0.0457722358	v2	Human-TCRB-PD2x	Published	08/10/2016 11:24:40	07/05/2016 03:54:28	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment,os censored status (0 = alive, 1=dead):os censored status (0 = alive, 1=dead) 1,overall survival (days):overall survival (days) 1526,pfs censored status (0 = pf, 1=progressed):pfs censored status (0 = pf, 1=progressed) 1,progression free survival (days):progression free survival (days) 428,treatment:nact,type of chemo:carbo/taxol	0.745341594591487	MSKCC- Snyder- P01-01		120.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCATCGATCTTCCCATTCCGACAATGAGCAGTTCTTCGGGCCA		Out	VDJ	3	192	0.02631218308894066		47	TCRBV03						TCRBJ02	TCRBJ02-01	01	5	2	8	5	3	13	26	38	43	41	56		TCRBV03-01,TCRBV03-02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									X+TCRBV03-X+TCRBJ02-01	TCRBV03		TCRBJ02-01*01	5660A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment				161	120	39	1	0	128	98	29	1	0	7297	5455	1791	51	0	0.0534780733	6.26096773	0.0522329435	6.63436937				479	0.25057435	0.0612282306	0.0457722358	v2	Human-TCRB-PD2x	Published	08/10/2016 11:24:40	07/05/2016 03:54:28	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment,os censored status (0 = alive, 1=dead):os censored status (0 = alive, 1=dead) 1,overall survival (days):overall survival (days) 1526,pfs censored status (0 = pf, 1=progressed):pfs censored status (0 = pf, 1=progressed) 1,progression free survival (days):progression free survival (days) 428,treatment:nact,type of chemo:carbo/taxol	0.745341594591487	MSKCC- Snyder- P01-01		120.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGCAGGAAGGACCACAGAACACTGAAGCTTTCTTTGGACAA		Out	VDJ	2	139	0.019048924215430998		44	TCRBV20						TCRBJ01	TCRBJ01-01	01	3	1	7	1	6	4	26	37	47	43	51		TCRBV20-01,TCRBV20-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									X+TCRBV20-X+TCRBJ01-01	TCRBV20		TCRBJ01-01*01	5660A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment				161	120	39	1	0	128	98	29	1	0	7297	5455	1791	51	0	0.0534780733	6.26096773	0.0522329435	6.63436937				479	0.25057435	0.0612282306	0.0457722358	v2	Human-TCRB-PD2x	Published	08/10/2016 11:24:40	07/05/2016 03:54:28	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment,os censored status (0 = alive, 1=dead):os censored status (0 = alive, 1=dead) 1,overall survival (days):overall survival (days) 1526,pfs censored status (0 = pf, 1=progressed):pfs censored status (0 = pf, 1=progressed) 1,progression free survival (days):progression free survival (days) 428,treatment:nact,type of chemo:carbo/taxol	0.745341594591487	MSKCC- Snyder- P01-01		120.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTGAGGGGCGGCTAACAGCAGGGACCGGGGAGCTGTTTTTTGGAGAA	CSAEGRLTAGTGELFF	In	VDJ	2	92	0.012607921063450734	0.016865261228230982	48	TCRBV20						TCRBJ02	TCRBJ02-02	01	5	4	3	5	16	0	26	35	-1	51	56		TCRBV20-01,TCRBV20-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CSAEGRLTAGTGELFF+TCRBV20-X+TCRBJ02-02	TCRBV20		TCRBJ02-02*01	5660A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment				161	120	39	1	0	128	98	29	1	0	7297	5455	1791	51	0	0.0534780733	6.26096773	0.0522329435	6.63436937				479	0.25057435	0.0612282306	0.0457722358	v2	Human-TCRB-PD2x	Published	08/10/2016 11:24:40	07/05/2016 03:54:28	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment,os censored status (0 = alive, 1=dead):os censored status (0 = alive, 1=dead) 1,overall survival (days):overall survival (days) 1526,pfs censored status (0 = pf, 1=progressed):pfs censored status (0 = pf, 1=progressed) 1,progression free survival (days):progression free survival (days) 428,treatment:nact,type of chemo:carbo/taxol	0.745341594591487	MSKCC- Snyder- P01-01		120.0	
GAGGGACTCAGCCGTGTATCTCTACGCCAGCAGCCGGGACAGCCGCACAGATACGCAGTATTTTGGCCCA	YASSRDSRTDTQYF	In	VDJ	1	76	0.010415239139372345	0.013932172318973418	42				TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	5	0	5	1	1	2	22	34	42	35	44	TCRBV07,TCRBV17	TCRBV07-03,TCRBV17-01												YASSRDSRTDTQYF+X+TCRBJ02-03		TCRBD01-01*01	TCRBJ02-03*01	5660A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment				161	120	39	1	0	128	98	29	1	0	7297	5455	1791	51	0	0.0534780733	6.26096773	0.0522329435	6.63436937				479	0.25057435	0.0612282306	0.0457722358	v2	Human-TCRB-PD2x	Published	08/10/2016 11:24:40	07/05/2016 03:54:28	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment,os censored status (0 = alive, 1=dead):os censored status (0 = alive, 1=dead) 1,overall survival (days):overall survival (days) 1526,pfs censored status (0 = pf, 1=progressed):pfs censored status (0 = pf, 1=progressed) 1,progression free survival (days):progression free survival (days) 428,treatment:nact,type of chemo:carbo/taxol	0.745341594591487	MSKCC- Snyder- P01-01		120.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCAGTCCGGGACATCAGGAAACACCATATATTTTGGAGAG	CASSQSGTSGNTIYF	In	VDJ	1	76	0.010415239139372345	0.013932172318973418	45	TCRBV03			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-03	01	3	0	6	4	4	3	26	40	50	44	53		TCRBV03-01,TCRBV03-02												CASSQSGTSGNTIYF+TCRBV03-X+TCRBJ01-03	TCRBV03	TCRBD01-01*01	TCRBJ01-03*01	5660A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment				161	120	39	1	0	128	98	29	1	0	7297	5455	1791	51	0	0.0534780733	6.26096773	0.0522329435	6.63436937				479	0.25057435	0.0612282306	0.0457722358	v2	Human-TCRB-PD2x	Published	08/10/2016 11:24:40	07/05/2016 03:54:28	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment,os censored status (0 = alive, 1=dead):os censored status (0 = alive, 1=dead) 1,overall survival (days):overall survival (days) 1526,pfs censored status (0 = pf, 1=progressed):pfs censored status (0 = pf, 1=progressed) 1,progression free survival (days):progression free survival (days) 428,treatment:nact,type of chemo:carbo/taxol	0.745341594591487	MSKCC- Snyder- P01-01		120.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCAGGAACTGTCCATTTCGTGTTAGACGAGCAGTACTTCGGGCCG		Out	VDJ	1	71	0.009730026038097849		49	TCRBV03						TCRBJ02	TCRBJ02-07	01	5	1	8	5	1	19	26	38	42	39	61		TCRBV03-01,TCRBV03-02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									X+TCRBV03-X+TCRBJ02-07	TCRBV03		TCRBJ02-07*01	5660A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment				161	120	39	1	0	128	98	29	1	0	7297	5455	1791	51	0	0.0534780733	6.26096773	0.0522329435	6.63436937				479	0.25057435	0.0612282306	0.0457722358	v2	Human-TCRB-PD2x	Published	08/10/2016 11:24:40	07/05/2016 03:54:28	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment,os censored status (0 = alive, 1=dead):os censored status (0 = alive, 1=dead) 1,overall survival (days):overall survival (days) 1526,pfs censored status (0 = pf, 1=progressed):pfs censored status (0 = pf, 1=progressed) 1,progression free survival (days):progression free survival (days) 428,treatment:nact,type of chemo:carbo/taxol	0.745341594591487	MSKCC- Snyder- P01-01		120.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCGCCATTTCCATTCCGACAATGAGCAGTTCTTCGGGCCA		Out	VDJ	1	68	0.00931889817733315		44	TCRBV03						TCRBJ02	TCRBJ02-01	01	5	4	6	5	2	11	26	38	42	40	53		TCRBV03-01,TCRBV03-02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									X+TCRBV03-X+TCRBJ02-01	TCRBV03		TCRBJ02-01*01	5660A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment				161	120	39	1	0	128	98	29	1	0	7297	5455	1791	51	0	0.0534780733	6.26096773	0.0522329435	6.63436937				479	0.25057435	0.0612282306	0.0457722358	v2	Human-TCRB-PD2x	Published	08/10/2016 11:24:40	07/05/2016 03:54:28	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment,os censored status (0 = alive, 1=dead):os censored status (0 = alive, 1=dead) 1,overall survival (days):overall survival (days) 1526,pfs censored status (0 = pf, 1=progressed):pfs censored status (0 = pf, 1=progressed) 1,progression free survival (days):progression free survival (days) 428,treatment:nact,type of chemo:carbo/taxol	0.745341594591487	MSKCC- Snyder- P01-01		120.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGATCAGGGGTAGGAAACACCATATATTTTGGAGAG	CSARSGVGNTIYF	In	VDJ	1	63	0.008633685076058654	0.01154903758020165	39	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-03	01	2	4	2	4	1	2	26	38	45	39	47		TCRBV20-01,TCRBV20-or09_02												CSARSGVGNTIYF+TCRBV20-X+TCRBJ01-03	TCRBV20	TCRBD01-01*01	TCRBJ01-03*01	5660A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment				161	120	39	1	0	128	98	29	1	0	7297	5455	1791	51	0	0.0534780733	6.26096773	0.0522329435	6.63436937				479	0.25057435	0.0612282306	0.0457722358	v2	Human-TCRB-PD2x	Published	08/10/2016 11:24:40	07/05/2016 03:54:28	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment,os censored status (0 = alive, 1=dead):os censored status (0 = alive, 1=dead) 1,overall survival (days):overall survival (days) 1526,pfs censored status (0 = pf, 1=progressed):pfs censored status (0 = pf, 1=progressed) 1,progression free survival (days):progression free survival (days) 428,treatment:nact,type of chemo:carbo/taxol	0.745341594591487	MSKCC- Snyder- P01-01		120.0	
ASCTCCCAGACATCTGTGTACTTSTGTGCCAGCAGAAATACCGGGACAGGGGAAACCGGGGAGCTGTTTTTTGGAGAA	CASRNTGTGETGELFF	In	VDJ	1	60	0.008222557215293956	0.010999083409715857	48	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-02	01	6	0	2	5	7	2	23	34	51	41	53	TCRBV06,TCRBV10													CASRNTGTGETGELFF+X+TCRBJ02-02	unresolved	TCRBD01-01*01	TCRBJ02-02*01	5660A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment				161	120	39	1	0	128	98	29	1	0	7297	5455	1791	51	0	0.0534780733	6.26096773	0.0522329435	6.63436937				479	0.25057435	0.0612282306	0.0457722358	v2	Human-TCRB-PD2x	Published	08/10/2016 11:24:40	07/05/2016 03:54:28	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment,os censored status (0 = alive, 1=dead):os censored status (0 = alive, 1=dead) 1,overall survival (days):overall survival (days) 1526,pfs censored status (0 = pf, 1=progressed):pfs censored status (0 = pf, 1=progressed) 1,progression free survival (days):progression free survival (days) 428,treatment:nact,type of chemo:carbo/taxol	0.745341594591487	MSKCC- Snyder- P01-01		120.0	
GGACTCRGCCRTGTATSKCTGTGCCAGCAGCTTAGATCCGGAGGGGTCCTACAATGAGCAGTTCTTCGGGCCA	CASSLDPEGSYNEQFF	In	VDJ	1	54	0.007400301493764561	0.009899175068744272	48	unresolved			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	0	10	0	1	3	1	18	35	44	38	45	TCRBV07,TCRBV11													CASSLDPEGSYNEQFF+X+TCRBJ02-01	unresolved	TCRBD02-01*02	TCRBJ02-01*01	5660A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment				161	120	39	1	0	128	98	29	1	0	7297	5455	1791	51	0	0.0534780733	6.26096773	0.0522329435	6.63436937				479	0.25057435	0.0612282306	0.0457722358	v2	Human-TCRB-PD2x	Published	08/10/2016 11:24:40	07/05/2016 03:54:28	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment,os censored status (0 = alive, 1=dead):os censored status (0 = alive, 1=dead) 1,overall survival (days):overall survival (days) 1526,pfs censored status (0 = pf, 1=progressed):pfs censored status (0 = pf, 1=progressed) 1,progression free survival (days):progression free survival (days) 428,treatment:nact,type of chemo:carbo/taxol	0.745341594591487	MSKCC- Snyder- P01-01		120.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGAGGTCCGGGACTAATGGAGACCCAGTACTTCGGGCCA	CSARGPGLMETQYF	In	VDJ	1	54	0.007400301493764561	0.009899175068744272	42	TCRBV20			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-05	01	1	0	9	5	4	3	26	39	50	43	53		TCRBV20-01,TCRBV20-or09_02				01,02								CSARGPGLMETQYF+TCRBV20-X+TCRBJ02-05	TCRBV20	TCRBD02-01	TCRBJ02-05*01	5660A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment				161	120	39	1	0	128	98	29	1	0	7297	5455	1791	51	0	0.0534780733	6.26096773	0.0522329435	6.63436937				479	0.25057435	0.0612282306	0.0457722358	v2	Human-TCRB-PD2x	Published	08/10/2016 11:24:40	07/05/2016 03:54:28	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment,os censored status (0 = alive, 1=dead):os censored status (0 = alive, 1=dead) 1,overall survival (days):overall survival (days) 1526,pfs censored status (0 = pf, 1=progressed):pfs censored status (0 = pf, 1=progressed) 1,progression free survival (days):progression free survival (days) 428,treatment:nact,type of chemo:carbo/taxol	0.745341594591487	MSKCC- Snyder- P01-01		120.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCACCAGTGAGGTGGGACAGAACAATGAGCAGTTCTTCGGGCCA	CATSEVGQNNEQFF	In	VDJ	1	53	0.007263258873509661	0.009715857011915673	42	TCRBV24			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	4	0	5	5	3	1	24	38	48	41	49		TCRBV24-01,TCRBV24-or09_02												CATSEVGQNNEQFF+TCRBV24-X+TCRBJ02-01	TCRBV24	TCRBD01-01*01	TCRBJ02-01*01	5660A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment				161	120	39	1	0	128	98	29	1	0	7297	5455	1791	51	0	0.0534780733	6.26096773	0.0522329435	6.63436937				479	0.25057435	0.0612282306	0.0457722358	v2	Human-TCRB-PD2x	Published	08/10/2016 11:24:40	07/05/2016 03:54:28	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment,os censored status (0 = alive, 1=dead):os censored status (0 = alive, 1=dead) 1,overall survival (days):overall survival (days) 1526,pfs censored status (0 = pf, 1=progressed):pfs censored status (0 = pf, 1=progressed) 1,progression free survival (days):progression free survival (days) 428,treatment:nact,type of chemo:carbo/taxol	0.745341594591487	MSKCC- Snyder- P01-01		120.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCTTGGATGCTCCATTTCATACATCATAATTCACCCCTCCACTTTGGGAAC		Out	VDJ	1	53	0.007263258873509661		55	TCRBV03						TCRBJ01	TCRBJ01-06	01	5	1	8	5	2	18	26	38	43	40	61		TCRBV03-01,TCRBV03-02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									X+TCRBV03-X+TCRBJ01-06	TCRBV03		TCRBJ01-06*01	5660A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment				161	120	39	1	0	128	98	29	1	0	7297	5455	1791	51	0	0.0534780733	6.26096773	0.0522329435	6.63436937				479	0.25057435	0.0612282306	0.0457722358	v2	Human-TCRB-PD2x	Published	08/10/2016 11:24:40	07/05/2016 03:54:28	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment,os censored status (0 = alive, 1=dead):os censored status (0 = alive, 1=dead) 1,overall survival (days):overall survival (days) 1526,pfs censored status (0 = pf, 1=progressed):pfs censored status (0 = pf, 1=progressed) 1,progression free survival (days):progression free survival (days) 428,treatment:nact,type of chemo:carbo/taxol	0.745341594591487	MSKCC- Snyder- P01-01		120.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCATGAGCAGTTCGTGTTAGACGAGCAGTACTTCGGGCCG		Out	VDJ	1	53	0.007263258873509661		44	TCRBV03						TCRBJ02	TCRBJ02-07	01	5	4	5	5	5	10	26	38	46	43	56		TCRBV03-01,TCRBV03-02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									X+TCRBV03-X+TCRBJ02-07	TCRBV03		TCRBJ02-07*01	5660A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment				161	120	39	1	0	128	98	29	1	0	7297	5455	1791	51	0	0.0534780733	6.26096773	0.0522329435	6.63436937				479	0.25057435	0.0612282306	0.0457722358	v2	Human-TCRB-PD2x	Published	08/10/2016 11:24:40	07/05/2016 03:54:28	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment,os censored status (0 = alive, 1=dead):os censored status (0 = alive, 1=dead) 1,overall survival (days):overall survival (days) 1526,pfs censored status (0 = pf, 1=progressed):pfs censored status (0 = pf, 1=progressed) 1,progression free survival (days):progression free survival (days) 428,treatment:nact,type of chemo:carbo/taxol	0.745341594591487	MSKCC- Snyder- P01-01		120.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGTATATGATGAATTCGGGGAGCTGTTTTTTGGAGAA	CSVYDEFGELFF	In	VDJ	1	52	0.007126216253254762	0.009532538955087076	36	TCRBV20						TCRBJ02	TCRBJ02-02	01	7	2	8	7	5	6	26	33	40	38	46		TCRBV20-01,TCRBV20-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CSVYDEFGELFF+TCRBV20-X+TCRBJ02-02	TCRBV20		TCRBJ02-02*01	5660A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment				161	120	39	1	0	128	98	29	1	0	7297	5455	1791	51	0	0.0534780733	6.26096773	0.0522329435	6.63436937				479	0.25057435	0.0612282306	0.0457722358	v2	Human-TCRB-PD2x	Published	08/10/2016 11:24:40	07/05/2016 03:54:28	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment,os censored status (0 = alive, 1=dead):os censored status (0 = alive, 1=dead) 1,overall survival (days):overall survival (days) 1526,pfs censored status (0 = pf, 1=progressed):pfs censored status (0 = pf, 1=progressed) 1,progression free survival (days):progression free survival (days) 428,treatment:nact,type of chemo:carbo/taxol	0.745341594591487	MSKCC- Snyder- P01-01		120.0	
GGGGGACTYGGCYGTGTATSTCTGTGCCAGCAGCTTGGTTTAGGGAAATGAAAAACTGTTTTTTGGCAGT	CASSLV*GNEKLFF	Stop	VDJ	1	51	0.006989173632999863		42	unresolved						TCRBJ01	TCRBJ01-04	01	4	0	8	5	7	0	22	35	-1	42	46	TCRBV07,TCRBV11			TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSLV*GNEKLFF+X+TCRBJ01-04	unresolved		TCRBJ01-04*01	5660A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment				161	120	39	1	0	128	98	29	1	0	7297	5455	1791	51	0	0.0534780733	6.26096773	0.0522329435	6.63436937				479	0.25057435	0.0612282306	0.0457722358	v2	Human-TCRB-PD2x	Published	08/10/2016 11:24:40	07/05/2016 03:54:28	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment,os censored status (0 = alive, 1=dead):os censored status (0 = alive, 1=dead) 1,overall survival (days):overall survival (days) 1526,pfs censored status (0 = pf, 1=progressed):pfs censored status (0 = pf, 1=progressed) 1,progression free survival (days):progression free survival (days) 428,treatment:nact,type of chemo:carbo/taxol	0.745341594591487	MSKCC- Snyder- P01-01		120.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGAGATGATCGTACTGGAAACACCATATATTTTGGAGAG	CSARDDRTGNTIYF	In	VDJ	1	50	0.006852131012744964	0.00916590284142988	42	TCRBV20						TCRBJ01	TCRBJ01-03	01	0	2	8	2	1	5	26	40	43	41	48		TCRBV20-01,TCRBV20-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CSARDDRTGNTIYF+TCRBV20-X+TCRBJ01-03	TCRBV20		TCRBJ01-03*01	5660A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment				161	120	39	1	0	128	98	29	1	0	7297	5455	1791	51	0	0.0534780733	6.26096773	0.0522329435	6.63436937				479	0.25057435	0.0612282306	0.0457722358	v2	Human-TCRB-PD2x	Published	08/10/2016 11:24:40	07/05/2016 03:54:28	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment,os censored status (0 = alive, 1=dead):os censored status (0 = alive, 1=dead) 1,overall survival (days):overall survival (days) 1526,pfs censored status (0 = pf, 1=progressed):pfs censored status (0 = pf, 1=progressed) 1,progression free survival (days):progression free survival (days) 428,treatment:nact,type of chemo:carbo/taxol	0.745341594591487	MSKCC- Snyder- P01-01		120.0	
GGGGGACTCRGCYRTGTATCTCTGTGCCAGCAGCCGACATCCTGGACTAGCGGGTGGCACCGGGGAGCTGTTTTTTGGAGAA	CASSRHPGLAGGTGELFF	In	VDJ	1	46	0.006303960531725367	0.008432630614115491	54	unresolved			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-02	01	5	1	4	4	9	3	22	34	54	43	57	TCRBV07,TCRBV11					01,02								CASSRHPGLAGGTGELFF+X+TCRBJ02-02	unresolved	TCRBD02-01	TCRBJ02-02*01	5660A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment				161	120	39	1	0	128	98	29	1	0	7297	5455	1791	51	0	0.0534780733	6.26096773	0.0522329435	6.63436937				479	0.25057435	0.0612282306	0.0457722358	v2	Human-TCRB-PD2x	Published	08/10/2016 11:24:40	07/05/2016 03:54:28	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment,os censored status (0 = alive, 1=dead):os censored status (0 = alive, 1=dead) 1,overall survival (days):overall survival (days) 1526,pfs censored status (0 = pf, 1=progressed):pfs censored status (0 = pf, 1=progressed) 1,progression free survival (days):progression free survival (days) 428,treatment:nact,type of chemo:carbo/taxol	0.745341594591487	MSKCC- Snyder- P01-01		120.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGAGGAGGACATTCCGCGGAGACCCAGTACTTCGGGCCA	CSARGGHSAETQYF	In	VDJ	1	43	0.005892832670960669	0.007882676443629697	42	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-05	01	1	1	6	5	2	7	26	39	46	41	53		TCRBV20-01,TCRBV20-or09_02												CSARGGHSAETQYF+TCRBV20-X+TCRBJ02-05	TCRBV20	TCRBD01-01*01	TCRBJ02-05*01	5660A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment				161	120	39	1	0	128	98	29	1	0	7297	5455	1791	51	0	0.0534780733	6.26096773	0.0522329435	6.63436937				479	0.25057435	0.0612282306	0.0457722358	v2	Human-TCRB-PD2x	Published	08/10/2016 11:24:40	07/05/2016 03:54:28	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment,os censored status (0 = alive, 1=dead):os censored status (0 = alive, 1=dead) 1,overall survival (days):overall survival (days) 1526,pfs censored status (0 = pf, 1=progressed):pfs censored status (0 = pf, 1=progressed) 1,progression free survival (days):progression free survival (days) 428,treatment:nact,type of chemo:carbo/taxol	0.745341594591487	MSKCC- Snyder- P01-01		120.0	
MAGAAGACTCAGCYSYGTATCTCTGCGCCAGCAGCCAACTGGCGGGGAGTTACGAGCAGTACTTCGGGCCG	CASSQLAGSYEQYF	In	VDJ	1	41	0.005618747430450871	0.007516040329972502	42	unresolved			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-07	01	2	7	3	4	3	3	23	38	47	41	50	TCRBV01,TCRBV04													CASSQLAGSYEQYF+X+TCRBJ02-07	unresolved	TCRBD02-01*01	TCRBJ02-07*01	5660A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment				161	120	39	1	0	128	98	29	1	0	7297	5455	1791	51	0	0.0534780733	6.26096773	0.0522329435	6.63436937				479	0.25057435	0.0612282306	0.0457722358	v2	Human-TCRB-PD2x	Published	08/10/2016 11:24:40	07/05/2016 03:54:28	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment,os censored status (0 = alive, 1=dead):os censored status (0 = alive, 1=dead) 1,overall survival (days):overall survival (days) 1526,pfs censored status (0 = pf, 1=progressed):pfs censored status (0 = pf, 1=progressed) 1,progression free survival (days):progression free survival (days) 428,treatment:nact,type of chemo:carbo/taxol	0.745341594591487	MSKCC- Snyder- P01-01		120.0	
ASCTCCCAGACATCTGTGTACTTSTGTGCCAGCACCGACCCCACAGGGGCCTCCCACAATATGGAGACCCAGTACTTCGGGCCA	CASTDPTGASHNMETQYF	In	VDJ	1	40	0.005481704810195971	0.007332722273143905	54	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-05	01	7	3	2	5	8	14	23	33	48	41	62	TCRBV06,TCRBV10													CASTDPTGASHNMETQYF+X+TCRBJ02-05	unresolved	TCRBD01-01*01	TCRBJ02-05*01	5660A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment				161	120	39	1	0	128	98	29	1	0	7297	5455	1791	51	0	0.0534780733	6.26096773	0.0522329435	6.63436937				479	0.25057435	0.0612282306	0.0457722358	v2	Human-TCRB-PD2x	Published	08/10/2016 11:24:40	07/05/2016 03:54:28	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment,os censored status (0 = alive, 1=dead):os censored status (0 = alive, 1=dead) 1,overall survival (days):overall survival (days) 1526,pfs censored status (0 = pf, 1=progressed):pfs censored status (0 = pf, 1=progressed) 1,progression free survival (days):progression free survival (days) 428,treatment:nact,type of chemo:carbo/taxol	0.745341594591487	MSKCC- Snyder- P01-01		120.0	
MAGAAGACTCAGCYSYGTATCTCTGCGCCAGCAGCCAAGAAGGGAGGTACCAAGAGACCCAGTACTTCGGGCCA	CASSQEGRYQETQYF	In	VDJ	1	40	0.005481704810195971	0.007332722273143905	45	unresolved			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-05	01	0	9	1	0	1	1	23	40	47	41	48	TCRBV01,TCRBV04													CASSQEGRYQETQYF+X+TCRBJ02-05	unresolved	TCRBD02-01*02	TCRBJ02-05*01	5660A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment				161	120	39	1	0	128	98	29	1	0	7297	5455	1791	51	0	0.0534780733	6.26096773	0.0522329435	6.63436937				479	0.25057435	0.0612282306	0.0457722358	v2	Human-TCRB-PD2x	Published	08/10/2016 11:24:40	07/05/2016 03:54:28	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment,os censored status (0 = alive, 1=dead):os censored status (0 = alive, 1=dead) 1,overall survival (days):overall survival (days) 1526,pfs censored status (0 = pf, 1=progressed):pfs censored status (0 = pf, 1=progressed) 1,progression free survival (days):progression free survival (days) 428,treatment:nact,type of chemo:carbo/taxol	0.745341594591487	MSKCC- Snyder- P01-01		120.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCGGGTAGCCACTATGGCTACACCTTCGGTTCG	CSAGSHYGYTF	In	VDJ	1	40	0.005481704810195971	0.007332722273143905	33	TCRBV20			TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-02	01	6	5	7	3	3	1	26	34	41	37	42		TCRBV20-01,TCRBV20-or09_02				01,02								CSAGSHYGYTF+TCRBV20-X+TCRBJ01-02	TCRBV20	TCRBD02-01	TCRBJ01-02*01	5660A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment				161	120	39	1	0	128	98	29	1	0	7297	5455	1791	51	0	0.0534780733	6.26096773	0.0522329435	6.63436937				479	0.25057435	0.0612282306	0.0457722358	v2	Human-TCRB-PD2x	Published	08/10/2016 11:24:40	07/05/2016 03:54:28	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment,os censored status (0 = alive, 1=dead):os censored status (0 = alive, 1=dead) 1,overall survival (days):overall survival (days) 1526,pfs censored status (0 = pf, 1=progressed):pfs censored status (0 = pf, 1=progressed) 1,progression free survival (days):progression free survival (days) 428,treatment:nact,type of chemo:carbo/taxol	0.745341594591487	MSKCC- Snyder- P01-01		120.0	
TYRGGRGACWCAGCWYKGTATTTCTGTGCCAGCAGCGTTCTTGCTAGTTCGACAGATACGCAGTATTTTGGCCCA	CASSVLASSTDTQYF	In	VDJ	1	39	0.005344662189941072	0.007149404216315307	45	unresolved			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-03	01	5	4	8	3	7	4	24	36	47	43	51	TCRBV09,TCRBV21					01,02								CASSVLASSTDTQYF+X+TCRBJ02-03	unresolved	TCRBD02-01	TCRBJ02-03*01	5660A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment				161	120	39	1	0	128	98	29	1	0	7297	5455	1791	51	0	0.0534780733	6.26096773	0.0522329435	6.63436937				479	0.25057435	0.0612282306	0.0457722358	v2	Human-TCRB-PD2x	Published	08/10/2016 11:24:40	07/05/2016 03:54:28	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment,os censored status (0 = alive, 1=dead):os censored status (0 = alive, 1=dead) 1,overall survival (days):overall survival (days) 1526,pfs censored status (0 = pf, 1=progressed):pfs censored status (0 = pf, 1=progressed) 1,progression free survival (days):progression free survival (days) 428,treatment:nact,type of chemo:carbo/taxol	0.745341594591487	MSKCC- Snyder- P01-01		120.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCAGCAGTTCTCGGACTGATGCCTACGAGCAGTACTTCGGGCCG	CASSSRTDAYEQYF	In	VDJ	1	38	0.0052076195696861725	0.006966086159486709	42	TCRBV24			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-07	01	6	1	10	2	4	4	24	36	45	40	49		TCRBV24-01,TCRBV24-or09_02				01,02								CASSSRTDAYEQYF+TCRBV24-X+TCRBJ02-07	TCRBV24	TCRBD02-01	TCRBJ02-07*01	5660A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment				161	120	39	1	0	128	98	29	1	0	7297	5455	1791	51	0	0.0534780733	6.26096773	0.0522329435	6.63436937				479	0.25057435	0.0612282306	0.0457722358	v2	Human-TCRB-PD2x	Published	08/10/2016 11:24:40	07/05/2016 03:54:28	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment,os censored status (0 = alive, 1=dead):os censored status (0 = alive, 1=dead) 1,overall survival (days):overall survival (days) 1526,pfs censored status (0 = pf, 1=progressed):pfs censored status (0 = pf, 1=progressed) 1,progression free survival (days):progression free survival (days) 428,treatment:nact,type of chemo:carbo/taxol	0.745341594591487	MSKCC- Snyder- P01-01		120.0	
TSRRGGACTCAGCYRTGTACTTCTGTGCCAGCAGCGGTGACAGGGGCCACCAGGATACGCAGTATTTTGGCCCA	CASSGDRGHQDTQYF	In	VDJ	1	37	0.005070576949431273	0.006782768102658112	45	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	6	2	2	6	4	7	23	34	46	38	53	TCRBV02,TCRBV12													CASSGDRGHQDTQYF+X+TCRBJ02-03	unresolved	TCRBD01-01*01	TCRBJ02-03*01	5660A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment				161	120	39	1	0	128	98	29	1	0	7297	5455	1791	51	0	0.0534780733	6.26096773	0.0522329435	6.63436937				479	0.25057435	0.0612282306	0.0457722358	v2	Human-TCRB-PD2x	Published	08/10/2016 11:24:40	07/05/2016 03:54:28	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment,os censored status (0 = alive, 1=dead):os censored status (0 = alive, 1=dead) 1,overall survival (days):overall survival (days) 1526,pfs censored status (0 = pf, 1=progressed):pfs censored status (0 = pf, 1=progressed) 1,progression free survival (days):progression free survival (days) 428,treatment:nact,type of chemo:carbo/taxol	0.745341594591487	MSKCC- Snyder- P01-01		120.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCTCGTTACGTCTTCTCTGAGACCCAGTACTTCGGGCCA		Out	VDJ	1	37	0.005070576949431273		43	TCRBV03						TCRBJ02	TCRBJ02-05	01	5	3	7	5	5	9	26	38	45	43	54		TCRBV03-01,TCRBV03-02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									X+TCRBV03-X+TCRBJ02-05	TCRBV03		TCRBJ02-05*01	5660A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment				161	120	39	1	0	128	98	29	1	0	7297	5455	1791	51	0	0.0534780733	6.26096773	0.0522329435	6.63436937				479	0.25057435	0.0612282306	0.0457722358	v2	Human-TCRB-PD2x	Published	08/10/2016 11:24:40	07/05/2016 03:54:28	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment,os censored status (0 = alive, 1=dead):os censored status (0 = alive, 1=dead) 1,overall survival (days):overall survival (days) 1526,pfs censored status (0 = pf, 1=progressed):pfs censored status (0 = pf, 1=progressed) 1,progression free survival (days):progression free survival (days) 428,treatment:nact,type of chemo:carbo/taxol	0.745341594591487	MSKCC- Snyder- P01-01		120.0	
CGACKCRGCYRTGTAYCTSTGTGCCAGCAGCCGGGACCACGGCATTTGGGAGCAGTACTTCGGGCCG	CASSRDHGIWEQYF	In	VDJ	1	34	0.004659449088666575	0.006232813932172319	42	unresolved						TCRBJ02	TCRBJ02-07	01	5	0	7	7	1	12	18	30	36	31	48	TCRBV07,TCRBV15			TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSRDHGIWEQYF+X+TCRBJ02-07	unresolved		TCRBJ02-07*01	5660A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment				161	120	39	1	0	128	98	29	1	0	7297	5455	1791	51	0	0.0534780733	6.26096773	0.0522329435	6.63436937				479	0.25057435	0.0612282306	0.0457722358	v2	Human-TCRB-PD2x	Published	08/10/2016 11:24:40	07/05/2016 03:54:28	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment,os censored status (0 = alive, 1=dead):os censored status (0 = alive, 1=dead) 1,overall survival (days):overall survival (days) 1526,pfs censored status (0 = pf, 1=progressed):pfs censored status (0 = pf, 1=progressed) 1,progression free survival (days):progression free survival (days) 428,treatment:nact,type of chemo:carbo/taxol	0.745341594591487	MSKCC- Snyder- P01-01		120.0	
AACCCAGGGACTCAGCTGTGTAYTTYTGTGCCAGCAGTTCGGGACAGCCCTACGAGCAGTACTTCGGGCCG	CASSSGQPYEQYF	In	VDJ	1	33	0.004522406468411676	0.006049495875343721	39	TCRBV12			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	4	0	5	2	1	1	26	39	47	40	48		TCRBV12-03,TCRBV12-04												CASSSGQPYEQYF+TCRBV12-X+TCRBJ02-07	TCRBV12	TCRBD01-01*01	TCRBJ02-07*01	5660A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment				161	120	39	1	0	128	98	29	1	0	7297	5455	1791	51	0	0.0534780733	6.26096773	0.0522329435	6.63436937				479	0.25057435	0.0612282306	0.0457722358	v2	Human-TCRB-PD2x	Published	08/10/2016 11:24:40	07/05/2016 03:54:28	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment,os censored status (0 = alive, 1=dead):os censored status (0 = alive, 1=dead) 1,overall survival (days):overall survival (days) 1526,pfs censored status (0 = pf, 1=progressed):pfs censored status (0 = pf, 1=progressed) 1,progression free survival (days):progression free survival (days) 428,treatment:nact,type of chemo:carbo/taxol	0.745341594591487	MSKCC- Snyder- P01-01		120.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCCAGCAGTTCTGGCTGGAAGACTGAAGCTTTCTTTGGACAA	CASSSGWKTEAFF	In	VDJ	1	32	0.004385363848156776	0.005866177818515124	39	TCRBV12						TCRBJ01	TCRBJ01-01	01	4	1	8	5	6	2	26	39	48	45	50		TCRBV12-03,TCRBV12-04		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSSGWKTEAFF+TCRBV12-X+TCRBJ01-01	TCRBV12		TCRBJ01-01*01	5660A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment				161	120	39	1	0	128	98	29	1	0	7297	5455	1791	51	0	0.0534780733	6.26096773	0.0522329435	6.63436937				479	0.25057435	0.0612282306	0.0457722358	v2	Human-TCRB-PD2x	Published	08/10/2016 11:24:40	07/05/2016 03:54:28	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment,os censored status (0 = alive, 1=dead):os censored status (0 = alive, 1=dead) 1,overall survival (days):overall survival (days) 1526,pfs censored status (0 = pf, 1=progressed):pfs censored status (0 = pf, 1=progressed) 1,progression free survival (days):progression free survival (days) 428,treatment:nact,type of chemo:carbo/taxol	0.745341594591487	MSKCC- Snyder- P01-01		120.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGAAGGGGGCATCACGAGCAGTACTTCGGGCCG	CSARRGHHEQYF	In	VDJ	1	31	0.004248321227901877	0.0056828597616865265	36	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	2	5	0	5	0	3	26	-1	45	38	48		TCRBV20-01,TCRBV20-or09_02												CSARRGHHEQYF+TCRBV20-X+TCRBJ02-07	TCRBV20	TCRBD01-01*01	TCRBJ02-07*01	5660A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment				161	120	39	1	0	128	98	29	1	0	7297	5455	1791	51	0	0.0534780733	6.26096773	0.0522329435	6.63436937				479	0.25057435	0.0612282306	0.0457722358	v2	Human-TCRB-PD2x	Published	08/10/2016 11:24:40	07/05/2016 03:54:28	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment,os censored status (0 = alive, 1=dead):os censored status (0 = alive, 1=dead) 1,overall survival (days):overall survival (days) 1526,pfs censored status (0 = pf, 1=progressed):pfs censored status (0 = pf, 1=progressed) 1,progression free survival (days):progression free survival (days) 428,treatment:nact,type of chemo:carbo/taxol	0.745341594591487	MSKCC- Snyder- P01-01		120.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCATCGGTAGTGAAAACACCATATATTTTGGAGAG	CASIGSENTIYF	In	VDJ	1	31	0.004248321227901877	0.0056828597616865265	36	TCRBV03			TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-03	01	7	5	8	6	4	3	26	36	43	40	46		TCRBV03-01,TCRBV03-02				01,02								CASIGSENTIYF+TCRBV03-X+TCRBJ01-03	TCRBV03	TCRBD02-01	TCRBJ01-03*01	5660A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment				161	120	39	1	0	128	98	29	1	0	7297	5455	1791	51	0	0.0534780733	6.26096773	0.0522329435	6.63436937				479	0.25057435	0.0612282306	0.0457722358	v2	Human-TCRB-PD2x	Published	08/10/2016 11:24:40	07/05/2016 03:54:28	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment,os censored status (0 = alive, 1=dead):os censored status (0 = alive, 1=dead) 1,overall survival (days):overall survival (days) 1526,pfs censored status (0 = pf, 1=progressed):pfs censored status (0 = pf, 1=progressed) 1,progression free survival (days):progression free survival (days) 428,treatment:nact,type of chemo:carbo/taxol	0.745341594591487	MSKCC- Snyder- P01-01		120.0	
TGGRGGACTCAGCYWTGTAYTTCTGTGCCAGCAGCTGGACTAGCGGGGCAGCAGATACGCAGTATTTTGGCCCA	CASSWTSGAADTQYF	In	VDJ	1	30	0.004111278607646978	0.005499541704857928	45	unresolved			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-03	01	4	1	3	4	1	3	23	35	48	36	51	TCRBV02,TCRBV09													CASSWTSGAADTQYF+X+TCRBJ02-03	unresolved	TCRBD02-01*01	TCRBJ02-03*01	5660A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment				161	120	39	1	0	128	98	29	1	0	7297	5455	1791	51	0	0.0534780733	6.26096773	0.0522329435	6.63436937				479	0.25057435	0.0612282306	0.0457722358	v2	Human-TCRB-PD2x	Published	08/10/2016 11:24:40	07/05/2016 03:54:28	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment,os censored status (0 = alive, 1=dead):os censored status (0 = alive, 1=dead) 1,overall survival (days):overall survival (days) 1526,pfs censored status (0 = pf, 1=progressed):pfs censored status (0 = pf, 1=progressed) 1,progression free survival (days):progression free survival (days) 428,treatment:nact,type of chemo:carbo/taxol	0.745341594591487	MSKCC- Snyder- P01-01		120.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCAGCAGTTCCCTGTACAGGGGCCTTCACGAGCAGTACTTCGGGCCG	CASSSLYRGLHEQYF	In	VDJ	1	30	0.004111278607646978	0.005499541704857928	45	TCRBV24			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	6	3	2	5	7	5	24	36	50	43	55		TCRBV24-01,TCRBV24-or09_02												CASSSLYRGLHEQYF+TCRBV24-X+TCRBJ02-07	TCRBV24	TCRBD01-01*01	TCRBJ02-07*01	5660A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment				161	120	39	1	0	128	98	29	1	0	7297	5455	1791	51	0	0.0534780733	6.26096773	0.0522329435	6.63436937				479	0.25057435	0.0612282306	0.0457722358	v2	Human-TCRB-PD2x	Published	08/10/2016 11:24:40	07/05/2016 03:54:28	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment,os censored status (0 = alive, 1=dead):os censored status (0 = alive, 1=dead) 1,overall survival (days):overall survival (days) 1526,pfs censored status (0 = pf, 1=progressed):pfs censored status (0 = pf, 1=progressed) 1,progression free survival (days):progression free survival (days) 428,treatment:nact,type of chemo:carbo/taxol	0.745341594591487	MSKCC- Snyder- P01-01		120.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGAGTCAGGAATCACTAGCACAGATACGCAGTATTTTGGCCCA		Out	VDJ	1	29	0.003974235987392079		46	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	1	4	4	0	1	7	26	39	44	40	51		TCRBV20-01,TCRBV20-or09_02												X+TCRBV20-X+TCRBJ02-03	TCRBV20	TCRBD01-01*01	TCRBJ02-03*01	5660A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment				161	120	39	1	0	128	98	29	1	0	7297	5455	1791	51	0	0.0534780733	6.26096773	0.0522329435	6.63436937				479	0.25057435	0.0612282306	0.0457722358	v2	Human-TCRB-PD2x	Published	08/10/2016 11:24:40	07/05/2016 03:54:28	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment,os censored status (0 = alive, 1=dead):os censored status (0 = alive, 1=dead) 1,overall survival (days):overall survival (days) 1526,pfs censored status (0 = pf, 1=progressed):pfs censored status (0 = pf, 1=progressed) 1,progression free survival (days):progression free survival (days) 428,treatment:nact,type of chemo:carbo/taxol	0.745341594591487	MSKCC- Snyder- P01-01		120.0	
CGACTCGGCYGTGTATSTCTGTGCCAGCAGCTTGGAACATCTAGGTGGCCCTCCCCTCTACGAGCAGTACTTCGGGCCG	CASSLEHLGGPPLYEQYF	In	VDJ	1	28	0.0038371933671371796	0.0051329055912007334	54	unresolved			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-07	01	2	4	8	3	7	13	19	33	44	40	57	TCRBV07,TCRBV11					01,02								CASSLEHLGGPPLYEQYF+X+TCRBJ02-07	unresolved	TCRBD02-01	TCRBJ02-07*01	5660A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment				161	120	39	1	0	128	98	29	1	0	7297	5455	1791	51	0	0.0534780733	6.26096773	0.0522329435	6.63436937				479	0.25057435	0.0612282306	0.0457722358	v2	Human-TCRB-PD2x	Published	08/10/2016 11:24:40	07/05/2016 03:54:28	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment,os censored status (0 = alive, 1=dead):os censored status (0 = alive, 1=dead) 1,overall survival (days):overall survival (days) 1526,pfs censored status (0 = pf, 1=progressed):pfs censored status (0 = pf, 1=progressed) 1,progression free survival (days):progression free survival (days) 428,treatment:nact,type of chemo:carbo/taxol	0.745341594591487	MSKCC- Snyder- P01-01		120.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCTCGAGGGGTCCATTTGAAAGACCTATGGCTACACCTTCGGTTCG		Out	VDJ	1	26	0.003563108126627381		50	TCRBV03						TCRBJ01	TCRBJ01-02	01	5	5	2	4	3	14	26	38	46	41	60		TCRBV03-01,TCRBV03-02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									X+TCRBV03-X+TCRBJ01-02	TCRBV03		TCRBJ01-02*01	5660A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment				161	120	39	1	0	128	98	29	1	0	7297	5455	1791	51	0	0.0534780733	6.26096773	0.0522329435	6.63436937				479	0.25057435	0.0612282306	0.0457722358	v2	Human-TCRB-PD2x	Published	08/10/2016 11:24:40	07/05/2016 03:54:28	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment,os censored status (0 = alive, 1=dead):os censored status (0 = alive, 1=dead) 1,overall survival (days):overall survival (days) 1526,pfs censored status (0 = pf, 1=progressed):pfs censored status (0 = pf, 1=progressed) 1,progression free survival (days):progression free survival (days) 428,treatment:nact,type of chemo:carbo/taxol	0.745341594591487	MSKCC- Snyder- P01-01		120.0	
GACTCGGCCGTGTATGTCTGTGCCAGTAGCTTAAGGGACAGGGATTATGGCTACACCTTCGGTTCG	CASSLRDRDYGYTF	In	VDJ	1	25	0.003426065506372482	0.00458295142071494	42				TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	2	0	3	5	1	2	18	33	43	34	45	TCRBV11,TCRBV12	TCRBV11-03,TCRBV12-02												CASSLRDRDYGYTF+X+TCRBJ01-02		TCRBD01-01*01	TCRBJ01-02*01	5660A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment				161	120	39	1	0	128	98	29	1	0	7297	5455	1791	51	0	0.0534780733	6.26096773	0.0522329435	6.63436937				479	0.25057435	0.0612282306	0.0457722358	v2	Human-TCRB-PD2x	Published	08/10/2016 11:24:40	07/05/2016 03:54:28	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment,os censored status (0 = alive, 1=dead):os censored status (0 = alive, 1=dead) 1,overall survival (days):overall survival (days) 1526,pfs censored status (0 = pf, 1=progressed):pfs censored status (0 = pf, 1=progressed) 1,progression free survival (days):progression free survival (days) 428,treatment:nact,type of chemo:carbo/taxol	0.745341594591487	MSKCC- Snyder- P01-01		120.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGAGTGGGGGTTGGAAACACCATATATTTTGGAGAG	CSARVGVGNTIYF	In	VDJ	1	25	0.003426065506372482	0.00458295142071494	39	TCRBV20						TCRBJ01	TCRBJ01-03	01	1	6	1	3	1	1	26	39	45	40	46		TCRBV20-01,TCRBV20-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CSARVGVGNTIYF+TCRBV20-X+TCRBJ01-03	TCRBV20		TCRBJ01-03*01	5660A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment				161	120	39	1	0	128	98	29	1	0	7297	5455	1791	51	0	0.0534780733	6.26096773	0.0522329435	6.63436937				479	0.25057435	0.0612282306	0.0457722358	v2	Human-TCRB-PD2x	Published	08/10/2016 11:24:40	07/05/2016 03:54:28	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment,os censored status (0 = alive, 1=dead):os censored status (0 = alive, 1=dead) 1,overall survival (days):overall survival (days) 1526,pfs censored status (0 = pf, 1=progressed):pfs censored status (0 = pf, 1=progressed) 1,progression free survival (days):progression free survival (days) 428,treatment:nact,type of chemo:carbo/taxol	0.745341594591487	MSKCC- Snyder- P01-01		120.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCTCAACGGCCTACGCACAGATACGCAGTATTTTGGCCCA	CASSLNGLRTDTQYF	In	VDJ	1	25	0.003426065506372482	0.00458295142071494	45	TCRBV03						TCRBJ02	TCRBJ02-03	01	4	9	0	1	5	4	26	39	47	44	51		TCRBV03-01,TCRBV03-02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSLNGLRTDTQYF+TCRBV03-X+TCRBJ02-03	TCRBV03		TCRBJ02-03*01	5660A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment				161	120	39	1	0	128	98	29	1	0	7297	5455	1791	51	0	0.0534780733	6.26096773	0.0522329435	6.63436937				479	0.25057435	0.0612282306	0.0457722358	v2	Human-TCRB-PD2x	Published	08/10/2016 11:24:40	07/05/2016 03:54:28	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment,os censored status (0 = alive, 1=dead):os censored status (0 = alive, 1=dead) 1,overall survival (days):overall survival (days) 1526,pfs censored status (0 = pf, 1=progressed):pfs censored status (0 = pf, 1=progressed) 1,progression free survival (days):progression free survival (days) 428,treatment:nact,type of chemo:carbo/taxol	0.745341594591487	MSKCC- Snyder- P01-01		120.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGAGGGACCGAATTCTACGAGCAGTACTTCGGGCCG	CSARGTEFYEQYF	In	VDJ	1	22	0.003014937645607784	0.004032997250229147	39	TCRBV20						TCRBJ02	TCRBJ02-07	01	1	1	7	3	0	6	26	-1	43	39	49		TCRBV20-01,TCRBV20-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CSARGTEFYEQYF+TCRBV20-X+TCRBJ02-07	TCRBV20		TCRBJ02-07*01	5660A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment				161	120	39	1	0	128	98	29	1	0	7297	5455	1791	51	0	0.0534780733	6.26096773	0.0522329435	6.63436937				479	0.25057435	0.0612282306	0.0457722358	v2	Human-TCRB-PD2x	Published	08/10/2016 11:24:40	07/05/2016 03:54:28	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment,os censored status (0 = alive, 1=dead):os censored status (0 = alive, 1=dead) 1,overall survival (days):overall survival (days) 1526,pfs censored status (0 = pf, 1=progressed):pfs censored status (0 = pf, 1=progressed) 1,progression free survival (days):progression free survival (days) 428,treatment:nact,type of chemo:carbo/taxol	0.745341594591487	MSKCC- Snyder- P01-01		120.0	
TYRGRRGACWCAGCMMKGTAYTTCTGTGCCAGCAGCGGGACAGGGGAAATAATAGTGGATCACTGAAGCTTTCTTTGGACAA		Out	VDJ	1	21	0.002877895025352885		52	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	6	0	2	4	1	14	23	34	45	35	59	TCRBV02,TCRBV21													X+X+TCRBJ01-01	unresolved	TCRBD01-01*01	TCRBJ01-01*01	5660A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment				161	120	39	1	0	128	98	29	1	0	7297	5455	1791	51	0	0.0534780733	6.26096773	0.0522329435	6.63436937				479	0.25057435	0.0612282306	0.0457722358	v2	Human-TCRB-PD2x	Published	08/10/2016 11:24:40	07/05/2016 03:54:28	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment,os censored status (0 = alive, 1=dead):os censored status (0 = alive, 1=dead) 1,overall survival (days):overall survival (days) 1526,pfs censored status (0 = pf, 1=progressed):pfs censored status (0 = pf, 1=progressed) 1,progression free survival (days):progression free survival (days) 428,treatment:nact,type of chemo:carbo/taxol	0.745341594591487	MSKCC- Snyder- P01-01		120.0	
AACCCAGGGACTCAGCTGTGTAYTTYTGTGCCAGCAGCGTAGAAGGGGGGGACGAGCAGTACTTCGGGCCG	CASSVEGGDEQYF	In	VDJ	1	20	0.0027408524050979853	0.0036663611365719525	39	TCRBV12			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-07	01	6	9	0	5	7	0	26	37	-1	44	51		TCRBV12-03,TCRBV12-04,TCRBV12-05												CASSVEGGDEQYF+TCRBV12-X+TCRBJ02-07	TCRBV12	TCRBD02-01*01	TCRBJ02-07*01	5660A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment				161	120	39	1	0	128	98	29	1	0	7297	5455	1791	51	0	0.0534780733	6.26096773	0.0522329435	6.63436937				479	0.25057435	0.0612282306	0.0457722358	v2	Human-TCRB-PD2x	Published	08/10/2016 11:24:40	07/05/2016 03:54:28	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment,os censored status (0 = alive, 1=dead):os censored status (0 = alive, 1=dead) 1,overall survival (days):overall survival (days) 1526,pfs censored status (0 = pf, 1=progressed):pfs censored status (0 = pf, 1=progressed) 1,progression free survival (days):progression free survival (days) 428,treatment:nact,type of chemo:carbo/taxol	0.745341594591487	MSKCC- Snyder- P01-01		120.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCCAGCAGTTTTGGGACGAGGCCTGAAGCTTTCTTTGGACAA	CASSFGTRPEAFF	In	VDJ	1	19	0.0026038097848430863	0.0034830430797433546	39	TCRBV12						TCRBJ01	TCRBJ01-01	01	3	0	7	6	1	5	26	40	46	41	51		TCRBV12-03,TCRBV12-04		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSFGTRPEAFF+TCRBV12-X+TCRBJ01-01	TCRBV12		TCRBJ01-01*01	5660A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment				161	120	39	1	0	128	98	29	1	0	7297	5455	1791	51	0	0.0534780733	6.26096773	0.0522329435	6.63436937				479	0.25057435	0.0612282306	0.0457722358	v2	Human-TCRB-PD2x	Published	08/10/2016 11:24:40	07/05/2016 03:54:28	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment,os censored status (0 = alive, 1=dead):os censored status (0 = alive, 1=dead) 1,overall survival (days):overall survival (days) 1526,pfs censored status (0 = pf, 1=progressed):pfs censored status (0 = pf, 1=progressed) 1,progression free survival (days):progression free survival (days) 428,treatment:nact,type of chemo:carbo/taxol	0.745341594591487	MSKCC- Snyder- P01-01		120.0	
CCAACCAGACCTCTCTGTACTTCTGTGCCAGCAGCCTGCCGGGGAACACTGAAGCTTTCTTTGGACAA	CASSLPGNTEAFF	In	VDJ	1	33	0.004522406468411676	0.006049495875343721	39	TCRBV27	TCRBV27-01	01	TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-01	01	6	8	4	1	5	0	23	34	-1	39	43						01,02							Vb 14	CASSLPGNTEAFF+TCRBV27-01+TCRBJ01-01	TCRBV27-01*01	TCRBD02-01	TCRBJ01-01*01	5660A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment				161	120	39	1	0	128	98	29	1	0	7297	5455	1791	51	0	0.0534780733	6.26096773	0.0522329435	6.63436937				479	0.25057435	0.0612282306	0.0457722358	v2	Human-TCRB-PD2x	Published	08/10/2016 11:24:40	07/05/2016 03:54:28	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment,os censored status (0 = alive, 1=dead):os censored status (0 = alive, 1=dead) 1,overall survival (days):overall survival (days) 1526,pfs censored status (0 = pf, 1=progressed):pfs censored status (0 = pf, 1=progressed) 1,progression free survival (days):progression free survival (days) 428,treatment:nact,type of chemo:carbo/taxol	0.745341594591487	MSKCC- Snyder- P01-01		120.0	
GAAGACAGCAGCATATATCTCTGCAGCGTTGAAGGCCGGGGGATCGGGAGAGAGGAACATAGCACAGATACGCAGTATTTTGGCCCA	CSVEGRGIGREEHSTDTQYF	In	VDJ	1	38	0.0052076195696861725	0.006966086159486709	60	TCRBV29	TCRBV29-01	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-03	01	1	8	2	0	2	18	21	34	42	36	60						01,02							Vb 4	CSVEGRGIGREEHSTDTQYF+TCRBV29-01+TCRBJ02-03	TCRBV29-01*01	TCRBD02-01	TCRBJ02-03*01	5660A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment				161	120	39	1	0	128	98	29	1	0	7297	5455	1791	51	0	0.0534780733	6.26096773	0.0522329435	6.63436937				479	0.25057435	0.0612282306	0.0457722358	v2	Human-TCRB-PD2x	Published	08/10/2016 11:24:40	07/05/2016 03:54:28	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment,os censored status (0 = alive, 1=dead):os censored status (0 = alive, 1=dead) 1,overall survival (days):overall survival (days) 1526,pfs censored status (0 = pf, 1=progressed):pfs censored status (0 = pf, 1=progressed) 1,progression free survival (days):progression free survival (days) 428,treatment:nact,type of chemo:carbo/taxol	0.745341594591487	MSKCC- Snyder- P01-01		120.0	
CCCTGAAGACAGCAGCATATATCTCTGCAGCGTCGCGACAGGGGTCGGAAATCAGCCCCAGCATTTTGGTGAT	CSVATGVGNQPQHF	In	VDJ	1	19	0.0026038097848430863	0.0034830430797433546	42	TCRBV29	TCRBV29-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	6	2	2	4	3	5	25	33	44	36	49													Vb 4	CSVATGVGNQPQHF+TCRBV29-01+TCRBJ01-05	TCRBV29-01*01	TCRBD01-01*01	TCRBJ01-05*01	5660A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment				161	120	39	1	0	128	98	29	1	0	7297	5455	1791	51	0	0.0534780733	6.26096773	0.0522329435	6.63436937				479	0.25057435	0.0612282306	0.0457722358	v2	Human-TCRB-PD2x	Published	08/10/2016 11:24:40	07/05/2016 03:54:28	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment,os censored status (0 = alive, 1=dead):os censored status (0 = alive, 1=dead) 1,overall survival (days):overall survival (days) 1526,pfs censored status (0 = pf, 1=progressed):pfs censored status (0 = pf, 1=progressed) 1,progression free survival (days):progression free survival (days) 428,treatment:nact,type of chemo:carbo/taxol	0.745341594591487	MSKCC- Snyder- P01-01		120.0	
TGTAMSCTCYCAGACATCTGTGTACTTCTGTGCCAGCAGTGAAGAAGCGGGGAACACCGGGAAGCTGTTTTTTGGAGAA	CASSEEAGNTGKLFF	In	VDJ	1	56	0.007674386734274359	0.010265811182401467	45	TCRBV06	unresolved		TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-02	01	1	6	3	12	1	10	24	40	48	41	58		TCRBV06-01,TCRBV06-04												CASSEEAGNTGKLFF+TCRBV06-X+TCRBJ02-02	unresolved	TCRBD02-01*01	TCRBJ02-02*01	5660A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment				161	120	39	1	0	128	98	29	1	0	7297	5455	1791	51	0	0.0534780733	6.26096773	0.0522329435	6.63436937				479	0.25057435	0.0612282306	0.0457722358	v2	Human-TCRB-PD2x	Published	08/10/2016 11:24:40	07/05/2016 03:54:28	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment,os censored status (0 = alive, 1=dead):os censored status (0 = alive, 1=dead) 1,overall survival (days):overall survival (days) 1526,pfs censored status (0 = pf, 1=progressed):pfs censored status (0 = pf, 1=progressed) 1,progression free survival (days):progression free survival (days) 428,treatment:nact,type of chemo:carbo/taxol	0.745341594591487	MSKCC- Snyder- P01-01		120.0	
ASCTCCCAGACATCTGTGTACTTSTGTGCCAGCAGTTACTCGATCGATGGGGCGGGCAGGGATAGCTTTCTTTGGACAA		Out	VDJ	1	31	0.004248321227901877		49	TCRBV06	unresolved					TCRBJ01	TCRBJ01-01	01	0	4	3	10	15	2	23	40	60	55	62		TCRBV06-05,TCRBV06-06,TCRBV06-08		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									X+TCRBV06-X+TCRBJ01-01	unresolved		TCRBJ01-01*01	5660A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment				161	120	39	1	0	128	98	29	1	0	7297	5455	1791	51	0	0.0534780733	6.26096773	0.0522329435	6.63436937				479	0.25057435	0.0612282306	0.0457722358	v2	Human-TCRB-PD2x	Published	08/10/2016 11:24:40	07/05/2016 03:54:28	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment,os censored status (0 = alive, 1=dead):os censored status (0 = alive, 1=dead) 1,overall survival (days):overall survival (days) 1526,pfs censored status (0 = pf, 1=progressed):pfs censored status (0 = pf, 1=progressed) 1,progression free survival (days):progression free survival (days) 428,treatment:nact,type of chemo:carbo/taxol	0.745341594591487	MSKCC- Snyder- P01-01		120.0	
CTCCCTCCCAGACATCTGTRTACTTSTGTGCCAGCTTGGGACTAGCGGGCGTAAACACCGGGGAGCTGTTTTTTGGAGAA	CASLGLAGVNTGELFF	In	VDJ	1	28	0.0038371933671371796	0.0051329055912007334	48	TCRBV06	unresolved		TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-02	01	8	0	4	2	2	4	26	35	49	37	53		TCRBV06-08,TCRBV06-09				01,02								CASLGLAGVNTGELFF+TCRBV06-X+TCRBJ02-02	unresolved	TCRBD02-01	TCRBJ02-02*01	5660A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment				161	120	39	1	0	128	98	29	1	0	7297	5455	1791	51	0	0.0534780733	6.26096773	0.0522329435	6.63436937				479	0.25057435	0.0612282306	0.0457722358	v2	Human-TCRB-PD2x	Published	08/10/2016 11:24:40	07/05/2016 03:54:28	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment,os censored status (0 = alive, 1=dead):os censored status (0 = alive, 1=dead) 1,overall survival (days):overall survival (days) 1526,pfs censored status (0 = pf, 1=progressed):pfs censored status (0 = pf, 1=progressed) 1,progression free survival (days):progression free survival (days) 428,treatment:nact,type of chemo:carbo/taxol	0.745341594591487	MSKCC- Snyder- P01-01		120.0	
CTCCCTCYCAGACWTCTGTKTACTTSTGTGCCAGCAGTGACGGCAGCGTCCCACAGATACGCAGTATTTTGGCCCA		Out	VDJ	1	27	0.0037001507468822806		44	TCRBV06	unresolved		TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-03	01	5	6	6	2	6	3	23	35	45	41	48		TCRBV06-07,TCRBV06-08				01,02								X+TCRBV06-X+TCRBJ02-03	unresolved	TCRBD02-01	TCRBJ02-03*01	5660A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment				161	120	39	1	0	128	98	29	1	0	7297	5455	1791	51	0	0.0534780733	6.26096773	0.0522329435	6.63436937				479	0.25057435	0.0612282306	0.0457722358	v2	Human-TCRB-PD2x	Published	08/10/2016 11:24:40	07/05/2016 03:54:28	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment,os censored status (0 = alive, 1=dead):os censored status (0 = alive, 1=dead) 1,overall survival (days):overall survival (days) 1526,pfs censored status (0 = pf, 1=progressed):pfs censored status (0 = pf, 1=progressed) 1,progression free survival (days):progression free survival (days) 428,treatment:nact,type of chemo:carbo/taxol	0.745341594591487	MSKCC- Snyder- P01-01		120.0	
CTCCCTCYCAGACWTCTGTKTACTTSTGTGCCAGCAGTTACTCCCCCGGAGGGACAGGGTGGTTGGATGAGCAGTTCTTCGGGCCA	CASSYSPGGTGWLDEQFF	In	VDJ	1	25	0.003426065506372482	0.00458295142071494	54	TCRBV06	unresolved		TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	0	0	3	8	7	7	23	40	56	47	63		TCRBV06-07,TCRBV06-08												CASSYSPGGTGWLDEQFF+TCRBV06-X+TCRBJ02-01	unresolved	TCRBD01-01*01	TCRBJ02-01*01	5660A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment				161	120	39	1	0	128	98	29	1	0	7297	5455	1791	51	0	0.0534780733	6.26096773	0.0522329435	6.63436937				479	0.25057435	0.0612282306	0.0457722358	v2	Human-TCRB-PD2x	Published	08/10/2016 11:24:40	07/05/2016 03:54:28	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment,os censored status (0 = alive, 1=dead):os censored status (0 = alive, 1=dead) 1,overall survival (days):overall survival (days) 1526,pfs censored status (0 = pf, 1=progressed):pfs censored status (0 = pf, 1=progressed) 1,progression free survival (days):progression free survival (days) 428,treatment:nact,type of chemo:carbo/taxol	0.745341594591487	MSKCC- Snyder- P01-01		120.0	
CTCCCTCTCAGACTTCTGTTTACTTCTGTGCCAGCAGTTACAAATTCAGACAGCCGCCTACGAGCAGTACTTCGGGCCG		Out	VDJ	1	35	0.004796491708921474		47	TCRBV06	TCRBV06-07	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	2	2	5	2	7	3	26	41	53	48	56														X+TCRBV06-07+TCRBJ02-07	TCRBV06-07*01	TCRBD01-01*01	TCRBJ02-07*01	5660A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment				161	120	39	1	0	128	98	29	1	0	7297	5455	1791	51	0	0.0534780733	6.26096773	0.0522329435	6.63436937				479	0.25057435	0.0612282306	0.0457722358	v2	Human-TCRB-PD2x	Published	08/10/2016 11:24:40	07/05/2016 03:54:28	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment,os censored status (0 = alive, 1=dead):os censored status (0 = alive, 1=dead) 1,overall survival (days):overall survival (days) 1526,pfs censored status (0 = pf, 1=progressed):pfs censored status (0 = pf, 1=progressed) 1,progression free survival (days):progression free survival (days) 428,treatment:nact,type of chemo:carbo/taxol	0.745341594591487	MSKCC- Snyder- P01-01		120.0	
CTCCCTCTCAGACTTCTGTTTACTTCTGTGCCAGCAGGGGTGCCCTACTTAAGAGCAGTACTTCGGGCCG		Out	VDJ	1	19	0.0026038097848430863		38	TCRBV06	TCRBV06-07	01				TCRBJ02	TCRBJ02-07	01	6	0	9	7	0	12	26	-1	40	37	52				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									X+TCRBV06-07+TCRBJ02-07	TCRBV06-07*01		TCRBJ02-07*01	5660A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment				161	120	39	1	0	128	98	29	1	0	7297	5455	1791	51	0	0.0534780733	6.26096773	0.0522329435	6.63436937				479	0.25057435	0.0612282306	0.0457722358	v2	Human-TCRB-PD2x	Published	08/10/2016 11:24:40	07/05/2016 03:54:28	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment,os censored status (0 = alive, 1=dead):os censored status (0 = alive, 1=dead) 1,overall survival (days):overall survival (days) 1526,pfs censored status (0 = pf, 1=progressed):pfs censored status (0 = pf, 1=progressed) 1,progression free survival (days):progression free survival (days) 428,treatment:nact,type of chemo:carbo/taxol	0.745341594591487	MSKCC- Snyder- P01-01		120.0	
GGACTCAGCCATGTATCGCTGTGCCAGCCGCCGACCGGGCCACAGGGCGCGGTTTCTACGAGCAGTACTTCGGGCCG		Out	VDJ	1	37	0.005070576949431273		52	TCRBV07	TCRBV07-07	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	8	3	3	3	13	8	19	28	47	41	55														X+TCRBV07-07+TCRBJ02-07	TCRBV07-07*01	TCRBD01-01*01	TCRBJ02-07*01	5660A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment				161	120	39	1	0	128	98	29	1	0	7297	5455	1791	51	0	0.0534780733	6.26096773	0.0522329435	6.63436937				479	0.25057435	0.0612282306	0.0457722358	v2	Human-TCRB-PD2x	Published	08/10/2016 11:24:40	07/05/2016 03:54:28	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment,os censored status (0 = alive, 1=dead):os censored status (0 = alive, 1=dead) 1,overall survival (days):overall survival (days) 1526,pfs censored status (0 = pf, 1=progressed):pfs censored status (0 = pf, 1=progressed) 1,progression free survival (days):progression free survival (days) 428,treatment:nact,type of chemo:carbo/taxol	0.745341594591487	MSKCC- Snyder- P01-01		120.0	
GGACTCAGCCATGTATCGCTGTGCCAGCAGCTTAGCTGGGGGACTAGCGGGGGGGCGCGAGCAGTTCTTCGGGCCA	CASSLAGGLAGGREQFF	In	VDJ	1	24	0.0032890228861175825	0.004399633363886343	51	TCRBV07	TCRBV07-07	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-01	01	0	0	0	10	3	3	19	36	55	39	58														CASSLAGGLAGGREQFF+TCRBV07-07+TCRBJ02-01	TCRBV07-07*01	TCRBD02-01*01	TCRBJ02-01*01	5660A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment				161	120	39	1	0	128	98	29	1	0	7297	5455	1791	51	0	0.0534780733	6.26096773	0.0522329435	6.63436937				479	0.25057435	0.0612282306	0.0457722358	v2	Human-TCRB-PD2x	Published	08/10/2016 11:24:40	07/05/2016 03:54:28	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment,os censored status (0 = alive, 1=dead):os censored status (0 = alive, 1=dead) 1,overall survival (days):overall survival (days) 1526,pfs censored status (0 = pf, 1=progressed):pfs censored status (0 = pf, 1=progressed) 1,progression free survival (days):progression free survival (days) 428,treatment:nact,type of chemo:carbo/taxol	0.745341594591487	MSKCC- Snyder- P01-01		120.0	
CAGAAGACTCAGCCCTGTATCTCTGCGCCAGCAGCCAAGTTGGGACAGACTATGGCTACACCTTCGGTTCG	CASSQVGTDYGYTF	In	VDJ	1	55	0.00753734411401946	0.01008249312557287	42	TCRBV04	TCRBV04-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	1	0	5	3	2	0	23	39	-1	41	48													Vb 7.1	CASSQVGTDYGYTF+TCRBV04-01+TCRBJ01-02	TCRBV04-01*01	TCRBD01-01*01	TCRBJ01-02*01	5660A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment				161	120	39	1	0	128	98	29	1	0	7297	5455	1791	51	0	0.0534780733	6.26096773	0.0522329435	6.63436937				479	0.25057435	0.0612282306	0.0457722358	v2	Human-TCRB-PD2x	Published	08/10/2016 11:24:40	07/05/2016 03:54:28	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment,os censored status (0 = alive, 1=dead):os censored status (0 = alive, 1=dead) 1,overall survival (days):overall survival (days) 1526,pfs censored status (0 = pf, 1=progressed):pfs censored status (0 = pf, 1=progressed) 1,progression free survival (days):progression free survival (days) 428,treatment:nact,type of chemo:carbo/taxol	0.745341594591487	MSKCC- Snyder- P01-01		120.0	
CCTCCTCCCAGACATCTGTATATTTCTGCGCCAGCAGTGAGTCGACCCGGGAGGCAAATGAGCAGTTCTTCGGGCCA	CASSESTREANEQFF	In	VDJ	1	33	0.004522406468411676	0.006049495875343721	45	TCRBV10	TCRBV10-01		TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	0	8	1	7	4	2	26	43	54	47	56			01,02										Vb 12	CASSESTREANEQFF+TCRBV10-01+TCRBJ02-01	TCRBV10-01	TCRBD02-01*02	TCRBJ02-01*01	5660A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment				161	120	39	1	0	128	98	29	1	0	7297	5455	1791	51	0	0.0534780733	6.26096773	0.0522329435	6.63436937				479	0.25057435	0.0612282306	0.0457722358	v2	Human-TCRB-PD2x	Published	08/10/2016 11:24:40	07/05/2016 03:54:28	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment,os censored status (0 = alive, 1=dead):os censored status (0 = alive, 1=dead) 1,overall survival (days):overall survival (days) 1526,pfs censored status (0 = pf, 1=progressed):pfs censored status (0 = pf, 1=progressed) 1,progression free survival (days):progression free survival (days) 428,treatment:nact,type of chemo:carbo/taxol	0.745341594591487	MSKCC- Snyder- P01-01		120.0	
GACGCAGCCATGTACCTGTGTGCCACCAGCAGGACAGGGTCTCCGCTCTGGGGCCAATGTCCTGACTTTCGGGGCC		Out	VDJ	3	172	0.023571330683842675		52	TCRBV15	TCRBV15-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-06	01	3	2	3	13	0	19	18	-1	39	32	58														X+TCRBV15-01+TCRBJ02-06	TCRBV15-01*01	TCRBD01-01*01	TCRBJ02-06*01	5660A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment				161	120	39	1	0	128	98	29	1	0	7297	5455	1791	51	0	0.0534780733	6.26096773	0.0522329435	6.63436937				479	0.25057435	0.0612282306	0.0457722358	v2	Human-TCRB-PD2x	Published	08/10/2016 11:24:40	07/05/2016 03:54:28	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment,os censored status (0 = alive, 1=dead):os censored status (0 = alive, 1=dead) 1,overall survival (days):overall survival (days) 1526,pfs censored status (0 = pf, 1=progressed):pfs censored status (0 = pf, 1=progressed) 1,progression free survival (days):progression free survival (days) 428,treatment:nact,type of chemo:carbo/taxol	0.745341594591487	MSKCC- Snyder- P01-01		120.0	
GACGCAGCCATGTACCTGTGTGCCACCAGCAGAGGCCCTGCGGGAGGGCCGGGGTATGAGCAGTTCTTCGGGCCA	CATSRGPAGGPGYEQFF	In	VDJ	2	107	0.014663560367274222	0.019615032080659945	51	TCRBV15	TCRBV15-01	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	1	7	0	8	5	7	18	34	48	39	55														CATSRGPAGGPGYEQFF+TCRBV15-01+TCRBJ02-01	TCRBV15-01*01	TCRBD02-01*02	TCRBJ02-01*01	5660A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment				161	120	39	1	0	128	98	29	1	0	7297	5455	1791	51	0	0.0534780733	6.26096773	0.0522329435	6.63436937				479	0.25057435	0.0612282306	0.0457722358	v2	Human-TCRB-PD2x	Published	08/10/2016 11:24:40	07/05/2016 03:54:28	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment,os censored status (0 = alive, 1=dead):os censored status (0 = alive, 1=dead) 1,overall survival (days):overall survival (days) 1526,pfs censored status (0 = pf, 1=progressed):pfs censored status (0 = pf, 1=progressed) 1,progression free survival (days):progression free survival (days) 428,treatment:nact,type of chemo:carbo/taxol	0.745341594591487	MSKCC- Snyder- P01-01		120.0	
GACGCAGCCATGTACCTGTGTGCCACCAGCAGAGCGACACCAGGGCCCTTTTTCTCTCTGGAAACACCATATATTTTGGAGAG		Out	VDJ	1	48	0.006578045772235165		59	TCRBV15	TCRBV15-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-03	01	1	4	3	0	6	10	18	34	45	40	55														X+TCRBV15-01+TCRBJ01-03	TCRBV15-01*01	TCRBD01-01*01	TCRBJ01-03*01	5660A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment				161	120	39	1	0	128	98	29	1	0	7297	5455	1791	51	0	0.0534780733	6.26096773	0.0522329435	6.63436937				479	0.25057435	0.0612282306	0.0457722358	v2	Human-TCRB-PD2x	Published	08/10/2016 11:24:40	07/05/2016 03:54:28	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment,os censored status (0 = alive, 1=dead):os censored status (0 = alive, 1=dead) 1,overall survival (days):overall survival (days) 1526,pfs censored status (0 = pf, 1=progressed):pfs censored status (0 = pf, 1=progressed) 1,progression free survival (days):progression free survival (days) 428,treatment:nact,type of chemo:carbo/taxol	0.745341594591487	MSKCC- Snyder- P01-01		120.0	
GACGCAGCCATGTACCTGTGTGCCACCAGCGAAGAGACAGGGAGGGCCAGGGGGACTGAAGCTTTCTTTGGACAA	CATSEETGRARGTEAFF	In	VDJ	1	27	0.0037001507468822806	0.004949587534372136	51	TCRBV15	TCRBV15-01	01				TCRBJ01	TCRBJ01-01	01	5	2	3	5	5	12	18	30	42	35	54				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CATSEETGRARGTEAFF+TCRBV15-01+TCRBJ01-01	TCRBV15-01*01		TCRBJ01-01*01	5660A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment				161	120	39	1	0	128	98	29	1	0	7297	5455	1791	51	0	0.0534780733	6.26096773	0.0522329435	6.63436937				479	0.25057435	0.0612282306	0.0457722358	v2	Human-TCRB-PD2x	Published	08/10/2016 11:24:40	07/05/2016 03:54:28	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment,os censored status (0 = alive, 1=dead):os censored status (0 = alive, 1=dead) 1,overall survival (days):overall survival (days) 1526,pfs censored status (0 = pf, 1=progressed):pfs censored status (0 = pf, 1=progressed) 1,progression free survival (days):progression free survival (days) 428,treatment:nact,type of chemo:carbo/taxol	0.745341594591487	MSKCC- Snyder- P01-01		120.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTGGCCGGGACAGGGAATGAAAAACTGTTTTTTGGCAGT	CASSLAGTGNEKLFF	In	VDJ	3	148	0.020282307797725094	0.027131072410632447	45	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-04	01	3	0	3	5	4	0	18	32	-1	36	45														CASSLAGTGNEKLFF+TCRBV11-03+TCRBJ01-04	TCRBV11-03*01	TCRBD01-01*01	TCRBJ01-04*01	5660A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment				161	120	39	1	0	128	98	29	1	0	7297	5455	1791	51	0	0.0534780733	6.26096773	0.0522329435	6.63436937				479	0.25057435	0.0612282306	0.0457722358	v2	Human-TCRB-PD2x	Published	08/10/2016 11:24:40	07/05/2016 03:54:28	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment,os censored status (0 = alive, 1=dead):os censored status (0 = alive, 1=dead) 1,overall survival (days):overall survival (days) 1526,pfs censored status (0 = pf, 1=progressed):pfs censored status (0 = pf, 1=progressed) 1,progression free survival (days):progression free survival (days) 428,treatment:nact,type of chemo:carbo/taxol	0.745341594591487	MSKCC- Snyder- P01-01		120.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTACGGACTAGCCAATTGGACATTCAGTACTTCGGCGCC	CASSLRTSQLDIQYF	In	VDJ	1	65	0.008907770316568453	0.011915673693858845	45	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-04	01	2	1	7	8	1	7	18	33	42	34	49						01,02								CASSLRTSQLDIQYF+TCRBV11-03+TCRBJ02-04	TCRBV11-03*01	TCRBD02-01	TCRBJ02-04*01	5660A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment				161	120	39	1	0	128	98	29	1	0	7297	5455	1791	51	0	0.0534780733	6.26096773	0.0522329435	6.63436937				479	0.25057435	0.0612282306	0.0457722358	v2	Human-TCRB-PD2x	Published	08/10/2016 11:24:40	07/05/2016 03:54:28	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment,os censored status (0 = alive, 1=dead):os censored status (0 = alive, 1=dead) 1,overall survival (days):overall survival (days) 1526,pfs censored status (0 = pf, 1=progressed):pfs censored status (0 = pf, 1=progressed) 1,progression free survival (days):progression free survival (days) 428,treatment:nact,type of chemo:carbo/taxol	0.745341594591487	MSKCC- Snyder- P01-01		120.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGTCCCTCTTCCTCTAGCGGGGGTTCCCCAGATACGCAGTATTTTGGCCCA	CASSPSSSSGGSPDTQYF	In	VDJ	1	41	0.005618747430450871	0.007516040329972502	54	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-03	01	6	4	2	4	11	5	18	29	50	40	55														CASSPSSSSGGSPDTQYF+TCRBV11-03+TCRBJ02-03	TCRBV11-03*01	TCRBD02-01*01	TCRBJ02-03*01	5660A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment				161	120	39	1	0	128	98	29	1	0	7297	5455	1791	51	0	0.0534780733	6.26096773	0.0522329435	6.63436937				479	0.25057435	0.0612282306	0.0457722358	v2	Human-TCRB-PD2x	Published	08/10/2016 11:24:40	07/05/2016 03:54:28	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment,os censored status (0 = alive, 1=dead):os censored status (0 = alive, 1=dead) 1,overall survival (days):overall survival (days) 1526,pfs censored status (0 = pf, 1=progressed):pfs censored status (0 = pf, 1=progressed) 1,progression free survival (days):progression free survival (days) 428,treatment:nact,type of chemo:carbo/taxol	0.745341594591487	MSKCC- Snyder- P01-01		120.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTCGGAGCGGGGGATGGGGAGACCCAGTACTTCGGGCCA	CASSFGAGDGETQYF	In	VDJ	1	41	0.005618747430450871	0.007516040329972502	45	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-05	01	3	6	2	5	3	5	18	32	43	35	48														CASSFGAGDGETQYF+TCRBV11-03+TCRBJ02-05	TCRBV11-03*01	TCRBD02-01*01	TCRBJ02-05*01	5660A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment				161	120	39	1	0	128	98	29	1	0	7297	5455	1791	51	0	0.0534780733	6.26096773	0.0522329435	6.63436937				479	0.25057435	0.0612282306	0.0457722358	v2	Human-TCRB-PD2x	Published	08/10/2016 11:24:40	07/05/2016 03:54:28	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment,os censored status (0 = alive, 1=dead):os censored status (0 = alive, 1=dead) 1,overall survival (days):overall survival (days) 1526,pfs censored status (0 = pf, 1=progressed):pfs censored status (0 = pf, 1=progressed) 1,progression free survival (days):progression free survival (days) 428,treatment:nact,type of chemo:carbo/taxol	0.745341594591487	MSKCC- Snyder- P01-01		120.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCGGTGACAAGCGATAATTCACCCCTCCACTTTGGGAAC		Out	VDJ	1	36	0.0049335343291763735		43	TCRBV11	TCRBV11-03	01				TCRBJ01	TCRBJ01-06	01	5	2	6	5	3	4	18	30	37	33	41				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									X+TCRBV11-03+TCRBJ01-06	TCRBV11-03*01		TCRBJ01-06*01	5660A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment				161	120	39	1	0	128	98	29	1	0	7297	5455	1791	51	0	0.0534780733	6.26096773	0.0522329435	6.63436937				479	0.25057435	0.0612282306	0.0457722358	v2	Human-TCRB-PD2x	Published	08/10/2016 11:24:40	07/05/2016 03:54:28	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment,os censored status (0 = alive, 1=dead):os censored status (0 = alive, 1=dead) 1,overall survival (days):overall survival (days) 1526,pfs censored status (0 = pf, 1=progressed):pfs censored status (0 = pf, 1=progressed) 1,progression free survival (days):progression free survival (days) 428,treatment:nact,type of chemo:carbo/taxol	0.745341594591487	MSKCC- Snyder- P01-01		120.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCCCTAGATCGGGGACTAACTCAGATACGCAGTATTTTGGCCCA	CASSPRSGTNSDTQYF	In	VDJ	1	36	0.0049335343291763735	0.006599450045829514	48	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-03	01	5	0	9	4	9	3	18	30	46	39	49						01,02								CASSPRSGTNSDTQYF+TCRBV11-03+TCRBJ02-03	TCRBV11-03*01	TCRBD02-01	TCRBJ02-03*01	5660A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment				161	120	39	1	0	128	98	29	1	0	7297	5455	1791	51	0	0.0534780733	6.26096773	0.0522329435	6.63436937				479	0.25057435	0.0612282306	0.0457722358	v2	Human-TCRB-PD2x	Published	08/10/2016 11:24:40	07/05/2016 03:54:28	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment,os censored status (0 = alive, 1=dead):os censored status (0 = alive, 1=dead) 1,overall survival (days):overall survival (days) 1526,pfs censored status (0 = pf, 1=progressed):pfs censored status (0 = pf, 1=progressed) 1,progression free survival (days):progression free survival (days) 428,treatment:nact,type of chemo:carbo/taxol	0.745341594591487	MSKCC- Snyder- P01-01		120.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCCTAAACCCCCAAGCAATCAGCCCCAGCATTTTGGTGAT		Out	VDJ	1	25	0.003426065506372482		44	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-05	01	5	4	9	1	0	8	18	-1	33	30	41						01,02								X+TCRBV11-03+TCRBJ01-05	TCRBV11-03*01	TCRBD02-01	TCRBJ01-05*01	5660A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment				161	120	39	1	0	128	98	29	1	0	7297	5455	1791	51	0	0.0534780733	6.26096773	0.0522329435	6.63436937				479	0.25057435	0.0612282306	0.0457722358	v2	Human-TCRB-PD2x	Published	08/10/2016 11:24:40	07/05/2016 03:54:28	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment,os censored status (0 = alive, 1=dead):os censored status (0 = alive, 1=dead) 1,overall survival (days):overall survival (days) 1526,pfs censored status (0 = pf, 1=progressed):pfs censored status (0 = pf, 1=progressed) 1,progression free survival (days):progression free survival (days) 428,treatment:nact,type of chemo:carbo/taxol	0.745341594591487	MSKCC- Snyder- P01-01		120.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCTAGTGGTTTTCGGGCCGAAGAGAGAGCCAAGAGACCCAGTACTTCGGGCCA		Out	VDJ	2	104	0.014252432506509524		50	TCRBV12	TCRBV12-05	01				TCRBJ02	TCRBJ02-05	01	3	8	0	1	2	11	26	40	46	42	57				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									X+TCRBV12-05+TCRBJ02-05	TCRBV12-05*01		TCRBJ02-05*01	5660A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment				161	120	39	1	0	128	98	29	1	0	7297	5455	1791	51	0	0.0534780733	6.26096773	0.0522329435	6.63436937				479	0.25057435	0.0612282306	0.0457722358	v2	Human-TCRB-PD2x	Published	08/10/2016 11:24:40	07/05/2016 03:54:28	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment,os censored status (0 = alive, 1=dead):os censored status (0 = alive, 1=dead) 1,overall survival (days):overall survival (days) 1526,pfs censored status (0 = pf, 1=progressed):pfs censored status (0 = pf, 1=progressed) 1,progression free survival (days):progression free survival (days) 428,treatment:nact,type of chemo:carbo/taxol	0.745341594591487	MSKCC- Snyder- P01-01		120.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCTAGTGGTTTGGTAAGGGCAGGGCCCTACGAGCAGTACTTCGGGCCG	CASGLVRAGPYEQYF	In	VDJ	2	88	0.012059750582431136	0.01613198900091659	45	TCRBV12	TCRBV12-05	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	0	4	3	2	5	1	26	43	53	48	54														CASGLVRAGPYEQYF+TCRBV12-05+TCRBJ02-07	TCRBV12-05*01	TCRBD01-01*01	TCRBJ02-07*01	5660A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment				161	120	39	1	0	128	98	29	1	0	7297	5455	1791	51	0	0.0534780733	6.26096773	0.0522329435	6.63436937				479	0.25057435	0.0612282306	0.0457722358	v2	Human-TCRB-PD2x	Published	08/10/2016 11:24:40	07/05/2016 03:54:28	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment,os censored status (0 = alive, 1=dead):os censored status (0 = alive, 1=dead) 1,overall survival (days):overall survival (days) 1526,pfs censored status (0 = pf, 1=progressed):pfs censored status (0 = pf, 1=progressed) 1,progression free survival (days):progression free survival (days) 428,treatment:nact,type of chemo:carbo/taxol	0.745341594591487	MSKCC- Snyder- P01-01		120.0	
ACCCAGGGACTCAGCTGTGTATTTTTGTGCTAGTGCCCCGTCGGGGAGCGGGAGGACGACGACACCGGGGAGCTGTTTTTTGGAGAA		Out	VDJ	1	30	0.004111278607646978		56	TCRBV12	TCRBV12-05	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-02	01	7	6	1	3	11	6	25	35	55	46	61														X+TCRBV12-05+TCRBJ02-02	TCRBV12-05*01	TCRBD02-01*02	TCRBJ02-02*01	5660A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment				161	120	39	1	0	128	98	29	1	0	7297	5455	1791	51	0	0.0534780733	6.26096773	0.0522329435	6.63436937				479	0.25057435	0.0612282306	0.0457722358	v2	Human-TCRB-PD2x	Published	08/10/2016 11:24:40	07/05/2016 03:54:28	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment,os censored status (0 = alive, 1=dead):os censored status (0 = alive, 1=dead) 1,overall survival (days):overall survival (days) 1526,pfs censored status (0 = pf, 1=progressed):pfs censored status (0 = pf, 1=progressed) 1,progression free survival (days):progression free survival (days) 428,treatment:nact,type of chemo:carbo/taxol	0.745341594591487	MSKCC- Snyder- P01-01		120.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCTTCCCACGGATTCGGGACAGGGGAAACAGATACGCAGTATTTTGGCCCA	CASHGFGTGETDTQYF	In	VDJ	1	19	0.0026038097848430863	0.0034830430797433546	48	TCRBV12	TCRBV12-05	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	11	0	2	3	12	2	26	32	54	44	56														CASHGFGTGETDTQYF+TCRBV12-05+TCRBJ02-03	TCRBV12-05*01	TCRBD01-01*01	TCRBJ02-03*01	5660A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment				161	120	39	1	0	128	98	29	1	0	7297	5455	1791	51	0	0.0534780733	6.26096773	0.0522329435	6.63436937				479	0.25057435	0.0612282306	0.0457722358	v2	Human-TCRB-PD2x	Published	08/10/2016 11:24:40	07/05/2016 03:54:28	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment,os censored status (0 = alive, 1=dead):os censored status (0 = alive, 1=dead) 1,overall survival (days):overall survival (days) 1526,pfs censored status (0 = pf, 1=progressed):pfs censored status (0 = pf, 1=progressed) 1,progression free survival (days):progression free survival (days) 428,treatment:nact,type of chemo:carbo/taxol	0.745341594591487	MSKCC- Snyder- P01-01		120.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTGACTCGTCGGGCCAGTCAGATACGCAGTATTTTGGCCCA	CASSDSSGQSDTQYF	In	VDJ	4	226	0.030971632177607237	0.04142988084326306	45	TCRBV06	TCRBV06-08	01				TCRBJ02	TCRBJ02-03	01	0	8	0	4	3	4	23	40	47	43	51				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSDSSGQSDTQYF+TCRBV06-08+TCRBJ02-03	TCRBV06-08*01		TCRBJ02-03*01	5660A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment				161	120	39	1	0	128	98	29	1	0	7297	5455	1791	51	0	0.0534780733	6.26096773	0.0522329435	6.63436937				479	0.25057435	0.0612282306	0.0457722358	v2	Human-TCRB-PD2x	Published	08/10/2016 11:24:40	07/05/2016 03:54:28	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment,os censored status (0 = alive, 1=dead):os censored status (0 = alive, 1=dead) 1,overall survival (days):overall survival (days) 1526,pfs censored status (0 = pf, 1=progressed):pfs censored status (0 = pf, 1=progressed) 1,progression free survival (days):progression free survival (days) 428,treatment:nact,type of chemo:carbo/taxol	0.745341594591487	MSKCC- Snyder- P01-01		120.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTACCCGGAAGCACTACTGGGTGGGACCCAGTACTTCGGGCCA	CASSYPEALLGGTQYF	In	VDJ	2	104	0.014252432506509524	0.01906507791017415	48	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-05	01	2	3	9	7	8	8	23	38	50	46	58						01,02								CASSYPEALLGGTQYF+TCRBV06-08+TCRBJ02-05	TCRBV06-08*01	TCRBD02-01	TCRBJ02-05*01	5660A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment				161	120	39	1	0	128	98	29	1	0	7297	5455	1791	51	0	0.0534780733	6.26096773	0.0522329435	6.63436937				479	0.25057435	0.0612282306	0.0457722358	v2	Human-TCRB-PD2x	Published	08/10/2016 11:24:40	07/05/2016 03:54:28	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment,os censored status (0 = alive, 1=dead):os censored status (0 = alive, 1=dead) 1,overall survival (days):overall survival (days) 1526,pfs censored status (0 = pf, 1=progressed):pfs censored status (0 = pf, 1=progressed) 1,progression free survival (days):progression free survival (days) 428,treatment:nact,type of chemo:carbo/taxol	0.745341594591487	MSKCC- Snyder- P01-01		120.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGCCGCTGGGCCGGGGAGCTGTTTTTTGGAGAA	CASSRWAGELFF	In	VDJ	2	98	0.013430176784980128	0.017965169569202567	36	TCRBV06	TCRBV06-08	01				TCRBJ02	TCRBJ02-02	01	6	0	9	6	5	0	23	34	-1	39	42				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSRWAGELFF+TCRBV06-08+TCRBJ02-02	TCRBV06-08*01		TCRBJ02-02*01	5660A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment				161	120	39	1	0	128	98	29	1	0	7297	5455	1791	51	0	0.0534780733	6.26096773	0.0522329435	6.63436937				479	0.25057435	0.0612282306	0.0457722358	v2	Human-TCRB-PD2x	Published	08/10/2016 11:24:40	07/05/2016 03:54:28	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment,os censored status (0 = alive, 1=dead):os censored status (0 = alive, 1=dead) 1,overall survival (days):overall survival (days) 1526,pfs censored status (0 = pf, 1=progressed):pfs censored status (0 = pf, 1=progressed) 1,progression free survival (days):progression free survival (days) 428,treatment:nact,type of chemo:carbo/taxol	0.745341594591487	MSKCC- Snyder- P01-01		120.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCACTACGGCCGGGGGATACTACGAGCAGTACTTCGGGCCG	CATTAGGYYEQYF	In	VDJ	1	81	0.011100452240646841	0.014848762603116407	39	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-07	01	10	8	2	3	7	3	23	30	43	37	46														CATTAGGYYEQYF+TCRBV06-08+TCRBJ02-07	TCRBV06-08*01	TCRBD02-01*01	TCRBJ02-07*01	5660A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment				161	120	39	1	0	128	98	29	1	0	7297	5455	1791	51	0	0.0534780733	6.26096773	0.0522329435	6.63436937				479	0.25057435	0.0612282306	0.0457722358	v2	Human-TCRB-PD2x	Published	08/10/2016 11:24:40	07/05/2016 03:54:28	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment,os censored status (0 = alive, 1=dead):os censored status (0 = alive, 1=dead) 1,overall survival (days):overall survival (days) 1526,pfs censored status (0 = pf, 1=progressed):pfs censored status (0 = pf, 1=progressed) 1,progression free survival (days):progression free survival (days) 428,treatment:nact,type of chemo:carbo/taxol	0.745341594591487	MSKCC- Snyder- P01-01		120.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGCCCACGAGGAAACACAGATACGCAGTATTTTGGCCCA	CASSPRGNTDTQYF	In	VDJ	1	73	0.010004111278607647	0.013382218148487626	42	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-03	01	6	11	1	2	5	3	23	34	43	39	46														CASSPRGNTDTQYF+TCRBV06-08+TCRBJ02-03	TCRBV06-08*01	TCRBD02-01*02	TCRBJ02-03*01	5660A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment				161	120	39	1	0	128	98	29	1	0	7297	5455	1791	51	0	0.0534780733	6.26096773	0.0522329435	6.63436937				479	0.25057435	0.0612282306	0.0457722358	v2	Human-TCRB-PD2x	Published	08/10/2016 11:24:40	07/05/2016 03:54:28	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment,os censored status (0 = alive, 1=dead):os censored status (0 = alive, 1=dead) 1,overall survival (days):overall survival (days) 1526,pfs censored status (0 = pf, 1=progressed):pfs censored status (0 = pf, 1=progressed) 1,progression free survival (days):progression free survival (days) 428,treatment:nact,type of chemo:carbo/taxol	0.745341594591487	MSKCC- Snyder- P01-01		120.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGCGGGGAGRACCCGGCTTACGAGCAGTACTTCGGGCCG	CASSGEXPAYEQYF	In	VDJ	1	62	0.008496642455803755	0.011365719523373053	42	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-07	01	6	9	1	4	2	8	23	34	42	36	50						unresolved								CASSGEXPAYEQYF+TCRBV06-08+TCRBJ02-07	TCRBV06-08*01	TCRBD02-01*02	TCRBJ02-07*01	5660A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment				161	120	39	1	0	128	98	29	1	0	7297	5455	1791	51	0	0.0534780733	6.26096773	0.0522329435	6.63436937				479	0.25057435	0.0612282306	0.0457722358	v2	Human-TCRB-PD2x	Published	08/10/2016 11:24:40	07/05/2016 03:54:28	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment,os censored status (0 = alive, 1=dead):os censored status (0 = alive, 1=dead) 1,overall survival (days):overall survival (days) 1526,pfs censored status (0 = pf, 1=progressed):pfs censored status (0 = pf, 1=progressed) 1,progression free survival (days):progression free survival (days) 428,treatment:nact,type of chemo:carbo/taxol	0.745341594591487	MSKCC- Snyder- P01-01		120.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTGACCCCCAGGGCCTCAATGGCTGCACCTTCGGTTCG	CASSDPQGLNGCTF	In	VDJ	1	50	0.006852131012744964	0.00916590284142988	42	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	5	4	3	13	6	12	23	35	46	41	58														CASSDPQGLNGCTF+TCRBV06-08+TCRBJ01-02	TCRBV06-08*01	TCRBD01-01*01	TCRBJ01-02*01	5660A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment				161	120	39	1	0	128	98	29	1	0	7297	5455	1791	51	0	0.0534780733	6.26096773	0.0522329435	6.63436937				479	0.25057435	0.0612282306	0.0457722358	v2	Human-TCRB-PD2x	Published	08/10/2016 11:24:40	07/05/2016 03:54:28	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment,os censored status (0 = alive, 1=dead):os censored status (0 = alive, 1=dead) 1,overall survival (days):overall survival (days) 1526,pfs censored status (0 = pf, 1=progressed):pfs censored status (0 = pf, 1=progressed) 1,progression free survival (days):progression free survival (days) 428,treatment:nact,type of chemo:carbo/taxol	0.745341594591487	MSKCC- Snyder- P01-01		120.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTCCCTCATTACAGCTGCAGTATTTTGGCCCA	CASSPSLQLQYF	In	VDJ	1	50	0.006852131012744964	0.00916590284142988	36	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	5	3	5	11	8	2	23	35	47	43	49														CASSPSLQLQYF+TCRBV06-08+TCRBJ02-03	TCRBV06-08*01	TCRBD01-01*01	TCRBJ02-03*01	5660A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment				161	120	39	1	0	128	98	29	1	0	7297	5455	1791	51	0	0.0534780733	6.26096773	0.0522329435	6.63436937				479	0.25057435	0.0612282306	0.0457722358	v2	Human-TCRB-PD2x	Published	08/10/2016 11:24:40	07/05/2016 03:54:28	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment,os censored status (0 = alive, 1=dead):os censored status (0 = alive, 1=dead) 1,overall survival (days):overall survival (days) 1526,pfs censored status (0 = pf, 1=progressed):pfs censored status (0 = pf, 1=progressed) 1,progression free survival (days):progression free survival (days) 428,treatment:nact,type of chemo:carbo/taxol	0.745341594591487	MSKCC- Snyder- P01-01		120.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTACTCGAGACTTGAGGGACAGACGGCTCCAAGAGACCCAGTACTTCGGGCCA		Out	VDJ	1	46	0.006303960531725367		58	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-05	01	0	0	5	1	9	6	23	40	56	49	62														X+TCRBV06-08+TCRBJ02-05	TCRBV06-08*01	TCRBD01-01*01	TCRBJ02-05*01	5660A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment				161	120	39	1	0	128	98	29	1	0	7297	5455	1791	51	0	0.0534780733	6.26096773	0.0522329435	6.63436937				479	0.25057435	0.0612282306	0.0457722358	v2	Human-TCRB-PD2x	Published	08/10/2016 11:24:40	07/05/2016 03:54:28	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment,os censored status (0 = alive, 1=dead):os censored status (0 = alive, 1=dead) 1,overall survival (days):overall survival (days) 1526,pfs censored status (0 = pf, 1=progressed):pfs censored status (0 = pf, 1=progressed) 1,progression free survival (days):progression free survival (days) 428,treatment:nact,type of chemo:carbo/taxol	0.745341594591487	MSKCC- Snyder- P01-01		120.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTACACTAGCGGGTACAATGAGCAGTTCTTCGGGCCA	CASSYTSGYNEQFF	In	VDJ	1	42	0.00575579005070577	0.0076993583868011	42	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	2	3	4	4	0	0	23	-1	-1	38	47						01,02								CASSYTSGYNEQFF+TCRBV06-08+TCRBJ02-01	TCRBV06-08*01	TCRBD02-01	TCRBJ02-01*01	5660A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment				161	120	39	1	0	128	98	29	1	0	7297	5455	1791	51	0	0.0534780733	6.26096773	0.0522329435	6.63436937				479	0.25057435	0.0612282306	0.0457722358	v2	Human-TCRB-PD2x	Published	08/10/2016 11:24:40	07/05/2016 03:54:28	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment,os censored status (0 = alive, 1=dead):os censored status (0 = alive, 1=dead) 1,overall survival (days):overall survival (days) 1526,pfs censored status (0 = pf, 1=progressed):pfs censored status (0 = pf, 1=progressed) 1,progression free survival (days):progression free survival (days) 428,treatment:nact,type of chemo:carbo/taxol	0.745341594591487	MSKCC- Snyder- P01-01		120.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTCGCCCCAGACAGGGGTCGGATACGCAGTATTTTGGCCCA	CASSRPRQGSDTQYF	In	VDJ	1	40	0.005481704810195971	0.007332722273143905	45	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	5	2	2	6	7	3	23	35	50	42	53														CASSRPRQGSDTQYF+TCRBV06-08+TCRBJ02-03	TCRBV06-08*01	TCRBD01-01*01	TCRBJ02-03*01	5660A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment				161	120	39	1	0	128	98	29	1	0	7297	5455	1791	51	0	0.0534780733	6.26096773	0.0522329435	6.63436937				479	0.25057435	0.0612282306	0.0457722358	v2	Human-TCRB-PD2x	Published	08/10/2016 11:24:40	07/05/2016 03:54:28	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment,os censored status (0 = alive, 1=dead):os censored status (0 = alive, 1=dead) 1,overall survival (days):overall survival (days) 1526,pfs censored status (0 = pf, 1=progressed):pfs censored status (0 = pf, 1=progressed) 1,progression free survival (days):progression free survival (days) 428,treatment:nact,type of chemo:carbo/taxol	0.745341594591487	MSKCC- Snyder- P01-01		120.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGCCCAACTAGCGGGGGGGCAGATACGCAGTATTTTGGCCCA	CASSPTSGGADTQYF	In	VDJ	1	39	0.005344662189941072	0.007149404216315307	45	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-03	01	6	3	0	4	4	0	23	34	-1	38	51														CASSPTSGGADTQYF+TCRBV06-08+TCRBJ02-03	TCRBV06-08*01	TCRBD02-01*01	TCRBJ02-03*01	5660A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment				161	120	39	1	0	128	98	29	1	0	7297	5455	1791	51	0	0.0534780733	6.26096773	0.0522329435	6.63436937				479	0.25057435	0.0612282306	0.0457722358	v2	Human-TCRB-PD2x	Published	08/10/2016 11:24:40	07/05/2016 03:54:28	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment,os censored status (0 = alive, 1=dead):os censored status (0 = alive, 1=dead) 1,overall survival (days):overall survival (days) 1526,pfs censored status (0 = pf, 1=progressed):pfs censored status (0 = pf, 1=progressed) 1,progression free survival (days):progression free survival (days) 428,treatment:nact,type of chemo:carbo/taxol	0.745341594591487	MSKCC- Snyder- P01-01		120.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTGGATTCCGACAGGGGGAAGCTTTCTTTGGACAA	CASSGFRQGEAFF	In	VDJ	1	29	0.003974235987392079	0.005316223648029331	39	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	5	2	2	8	7	0	23	35	-1	42	50														CASSGFRQGEAFF+TCRBV06-08+TCRBJ01-01	TCRBV06-08*01	TCRBD01-01*01	TCRBJ01-01*01	5660A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment				161	120	39	1	0	128	98	29	1	0	7297	5455	1791	51	0	0.0534780733	6.26096773	0.0522329435	6.63436937				479	0.25057435	0.0612282306	0.0457722358	v2	Human-TCRB-PD2x	Published	08/10/2016 11:24:40	07/05/2016 03:54:28	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment,os censored status (0 = alive, 1=dead):os censored status (0 = alive, 1=dead) 1,overall survival (days):overall survival (days) 1526,pfs censored status (0 = pf, 1=progressed):pfs censored status (0 = pf, 1=progressed) 1,progression free survival (days):progression free survival (days) 428,treatment:nact,type of chemo:carbo/taxol	0.745341594591487	MSKCC- Snyder- P01-01		120.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCGCCGGGACAAACAATCAGCCCCAGCATTTTGGTGAT	CASAGTNNQPQHF	In	VDJ	1	25	0.003426065506372482	0.00458295142071494	39	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	8	0	6	3	3	2	23	32	41	35	43														CASAGTNNQPQHF+TCRBV06-08+TCRBJ01-05	TCRBV06-08*01	TCRBD01-01*01	TCRBJ01-05*01	5660A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment				161	120	39	1	0	128	98	29	1	0	7297	5455	1791	51	0	0.0534780733	6.26096773	0.0522329435	6.63436937				479	0.25057435	0.0612282306	0.0457722358	v2	Human-TCRB-PD2x	Published	08/10/2016 11:24:40	07/05/2016 03:54:28	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment,os censored status (0 = alive, 1=dead):os censored status (0 = alive, 1=dead) 1,overall survival (days):overall survival (days) 1526,pfs censored status (0 = pf, 1=progressed):pfs censored status (0 = pf, 1=progressed) 1,progression free survival (days):progression free survival (days) 428,treatment:nact,type of chemo:carbo/taxol	0.745341594591487	MSKCC- Snyder- P01-01		120.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCGGGGACAGGATACTACAATGAGCAGTTCTTCGGGCCA	CASSGTGYYNEQFF	In	VDJ	6	334	0.04577223516513636	0.061228230980751606	42	TCRBV18	TCRBV18-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	6	0	4	3	1	3	24	35	44	36	47													Vb 18	CASSGTGYYNEQFF+TCRBV18-01+TCRBJ02-01	TCRBV18-01*01	TCRBD01-01*01	TCRBJ02-01*01	5660A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment				161	120	39	1	0	128	98	29	1	0	7297	5455	1791	51	0	0.0534780733	6.26096773	0.0522329435	6.63436937				479	0.25057435	0.0612282306	0.0457722358	v2	Human-TCRB-PD2x	Published	08/10/2016 11:24:40	07/05/2016 03:54:28	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment,os censored status (0 = alive, 1=dead):os censored status (0 = alive, 1=dead) 1,overall survival (days):overall survival (days) 1526,pfs censored status (0 = pf, 1=progressed):pfs censored status (0 = pf, 1=progressed) 1,progression free survival (days):progression free survival (days) 428,treatment:nact,type of chemo:carbo/taxol	0.745341594591487	MSKCC- Snyder- P01-01		120.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCACCGGGACTAGAAAGAGACCCAGTACTTCGGGCCA		Out	VDJ	3	180	0.02466767164588187		40	TCRBV18	TCRBV18-01	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-05	01	3	0	8	3	0	1	24	-1	46	38	47						01,02							Vb 18	X+TCRBV18-01+TCRBJ02-05	TCRBV18-01*01	TCRBD02-01	TCRBJ02-05*01	5660A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment				161	120	39	1	0	128	98	29	1	0	7297	5455	1791	51	0	0.0534780733	6.26096773	0.0522329435	6.63436937				479	0.25057435	0.0612282306	0.0457722358	v2	Human-TCRB-PD2x	Published	08/10/2016 11:24:40	07/05/2016 03:54:28	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment,os censored status (0 = alive, 1=dead):os censored status (0 = alive, 1=dead) 1,overall survival (days):overall survival (days) 1526,pfs censored status (0 = pf, 1=progressed):pfs censored status (0 = pf, 1=progressed) 1,progression free survival (days):progression free survival (days) 428,treatment:nact,type of chemo:carbo/taxol	0.745341594591487	MSKCC- Snyder- P01-01		120.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCACGAACAGGGTTCTTCAATGAGCAGTTCTTCGGGCCA	CASSRTGFFNEQFF	In	VDJ	1	54	0.007400301493764561	0.009899175068744272	42	TCRBV18	TCRBV18-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	4	3	3	6	2	5	24	37	45	39	50													Vb 18	CASSRTGFFNEQFF+TCRBV18-01+TCRBJ02-01	TCRBV18-01*01	TCRBD01-01*01	TCRBJ02-01*01	5660A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment				161	120	39	1	0	128	98	29	1	0	7297	5455	1791	51	0	0.0534780733	6.26096773	0.0522329435	6.63436937				479	0.25057435	0.0612282306	0.0457722358	v2	Human-TCRB-PD2x	Published	08/10/2016 11:24:40	07/05/2016 03:54:28	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Tissue,Treatment Status:Pre-Treatment,os censored status (0 = alive, 1=dead):os censored status (0 = alive, 1=dead) 1,overall survival (days):overall survival (days) 1526,pfs censored status (0 = pf, 1=progressed):pfs censored status (0 = pf, 1=progressed) 1,progression free survival (days):progression free survival (days) 428,treatment:nact,type of chemo:carbo/taxol	0.745341594591487	MSKCC- Snyder- P01-01		120.0	
